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ABSTRACT 
 
THE ROLE OF METASTASIS INDUCING PROTEINS IN ENDOMETRIAL 
CANCER 
 
Riya Susan Raju 
 
INTRODUCTION  
Prognosis of women who develop advanced endometrial cancer is poor, with a 5 year 
survival rate of only 45% and 25% for stages III and IV respectively.  Distant 
metastasis of malignant endometrial cells beyond the primary focus contributes to the 
advanced disease stages. A group of proteins, known as metastasis-inducing proteins 
(MIPs), have been shown to induce cellular invasion and metastasis, specifically 
AGR2, S100A4, S100P and Osteopontin (OPN). 
METHODS  
To investigate the expression of these four MIPs in endometrial cancer, and compare 
it to the endometrium of fertile control and postmenopausal women. Endometrial 
samples were collected from 55 women; 30 with endometrial cancer, 15 normal fertile 
control endometrium in the proliferative phase of the cycle and 10 postmenopausal. 
The expression of MIPs was evaluated by immunohistochemistry and confirmatory 
testing was undertaken with reverse transcriptase PCR. 
RESULTS 
All endometrial cancer samples showed a significantly increased immuno-reactivity 
to S100P (Stromal, #! $! %&%''() and S100A4 (Stromal, #! $! %&%')*) compared to 
benign endometrium. However OPN was virtually absent (Glands p = 0.0047, luminal 
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epithelium p=0.0018) in endometrial cancer cells. All postmenopausal samples 
showed a significantly decreased immuno-reactivity to all the MIPs (OPN, p = 0.0001, 
S100P, p = 0.0002, AGR2, p > 0.0001, S100A4, p = 0.0004) compared to endometrial 
cancer cells. RT-PCR results confirmed IHC results for the expression of S100P, 
AGR2 and S100A4, but contradicted OPN IHC results. The RT-PCR results gained 
were not statistically significant. 
DISCUSSION 
This data provides an interesting insight into the metastatic process of endometrial 
cancer. My results suggest that all four MIPs play a key role in metastasis of 
endometrial cancer, in comparison to the normal postmenopausal endometrium. 
Further research is required to understand the extent of the involvement OPN, S100P, 
AGR2 and S100A4 in inducing the metastatic process&!
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1 INTRODUCTION 
 
 
 
The human endometrium plays a dynamic role in ensuring uterine cavity patency, 
implantation and undergoes cyclical regeneration. Menstruation is cyclically 
synchronized to the excretion of hormones by the ovaries. Towards the end of the 
female reproductive period the depletion of oocytes and reduction in levels of 
oestrogen and progesterone leads to the cessation of menstruation. This is otherwise 
known as the menopause. Following this period (post-menopause), the endometrium 
can be exposed to high levels of unopposed oestrogen (with the absence of 
progesterone), which increases the risk of endometrial proliferation, hyperplasia and 
carcinoma. The distant spread of advanced cancerous endometrial cells beyond the 
primary focus, otherwise known as metastasis, is associated with increased mortality. 
The metastatic process is poorly understood and extensive research is required. It has 
been postulated that cellular processes such as increased mobility, proliferation, 
survival of cancerous cells etc may play an important role in allowing cells to adhere 
and continue growing in a hostile environment.  Some researchers suggest that there 
are specific types of cells, chemokines, proteins, enzymes, or immune cells within the 
cancer that can have the ability to initiate the metastasis process. We aim to further 
understand the metastatic process in endometrial cancer, by endeavoring to identify 
cancerous cells that have a tendency to metastasise. This would provide therapeutic 
targets for new treatment, improving prognosis and reducing mortality rates.  
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1.1 THE ENDOMETRIUM 
 
 
The uterine cavity is a single camber organ comprised of (from outside): the 
peritoneum which consists of the broad and suspensory ligaments; the peritetrium a 
thin serosal lining, the myometrium, a fibromuscular wall and finally the innermost 
two-layered modified mucosa, the endometrium (Edmonds & Dewhurst 2007; 
Critchley & Saunders 2009).  
The uterine artery supplies blood to the uterus, which is derived from the anterior 
division of the internal iliac artery. The uterine artery anastomoses with the ovarian 
artery creating arcuate branches supplying the myometrium and endometrium via the 
spiral arteries (Edmonds & Dewhurst 2007; Mutter & Ferenczy 2001).  
The endometrium is a diverse and dynamic tissue primarily preparing for implantation 
and functioning as the decidua during pregnancy. If pregnancy is not established, the 
endometrium continues to undergo well-organised cycles of menstruation, 
proliferation differentiation and regeneration (Jabbour et al 2006; Gregory et al 2002) 
The endometrium can be identified as having two layers, the functional layer (stratum 
functionalis) and the basal layer (stratum basalis). The functionalis represents the 
upper layer of the endometrium and consists of a superficial layer with a few simple 
tubular glands set in an abundant vascularised stroma (zona compacta) and a deeper 
layer with increased number of glands, but relatively less stroma (zona spongiosa). 
This layer is shed once a month during menstruation and is regenerated from the 
underlying basalis, which projects into the myometrium (Jimenez-Ayala & Jimenez-
Ayala Portillo 2008; Jabbour et al 2006). The activity and structure of the functionalis 
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is highly responsive to the hormones cyclically produced by the ovaries, in 
comparison to the basalis.  
The menstrual cycle is a highly regulated sequence of events, which involves an 
intimate relationship between the hypothalamus, pituitary, ovaries and uterus. It is 
predominantly synchronized with the ovarian cycle (Edmonds & Dewhurst 2007; 
Critchley & Saunders 2009). Ovarian steroids, oestrogen and progesterone play a 
crucial role in regulating the changes seen in the endometrial structure during the 
menstrual cycle. Following the oestrogen primed endometrium, progesterone is 
essential for the establishment and maintenance of pregnancy (Jabbour et al 2006).  
There are three key phases of the 28-30 day menstrual cycle: The menstrual phase, in 
which the endometrium is shed following reduced levels of progesterone, in response 
to a failed implantation. The oestrogen driven proliferative phase, where the 
endometrium rapidly regenerates and proliferates, follows this and is also well 
synchronised with the growth and maturation of an oocyte and its follicle. The 
secretory phase, in conjunction with the final maturation and release of the oocyte, is 
dominated by progesterone resulting in endometrial differentiation (Jabbour et al 
2006; Edmonds & Dewhurst 2007}.  
Towards the end of the reproductive life span women go through menopause, at the 
average age of 51 years (Edmonds & Dewhurst 2007). Menopause is defined as the 
last menstrual period, from the Greek “Menos” meaning month and “Pausis” meaning 
cessation. It can only be diagnosed retrospectively after a minimum one year of 
amenorrhoea. The reduction and ultimate depletion of oocytes is the key in the 
cessation of menstruation. Menopause is also associated with a permanent cessation 
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of progesterone production and reduced levels of oestrogen available to the 
endometrium.  
Following both the physiological decline in ovarian function and reduced levels of 
ovarian hormone levels, over a few years the non-functioning endometrium 
progressively changes to an atrophic endometrium. Atrophic endometrium is very thin, 
consisting of narrow glands lined by a low epithelium set in a dense fibrous stroma of 
spindle cells. It is near impossible to distinguish the two layers of the endometrium, 
functionalis and basalis, in an atrophic endometrium (Jimenez-Ayala & Jimenez-
Ayala Portillo 2008; Nalaboff et al 2001). 
The life expectancy of women is steadily rising, and is currently at 82 years of age in 
the UK, hence increasing the time spent living with menopause and its effects 
(Edmonds & Dewhurst 2007). Quality of life can be severely affected in women in 
their post-menopausal phase.  Early menopausal effects include vasomotor and 
psychological changes, and more long term is increased risk in developing 
osteoporosis, cardiovascular problems and dementia (Edmonds & Dewhurst 2007).  
Some post-menopausal women are exposed to different levels of unopposed 
oestrogen, i.e. in the absence of progesterone. This continuing exposure can lead to 
abnormal endometrial proliferation, hyperplasia and in extreme cases carcinoma 
(Edmonds & Dewhurst 2007). Excess unopposed oestrogen is a risk factor for 
endometrial hyperplasia that can predispose to endometrial carcinoma, along with 
obesity and null parity. With the epidemic of obesity and rising life expectancy there 
is no surprise the incidence of endometrial hyperplasia and cancer is rising. 
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1.2 ENDOMETRIAL CANCER !
 
Cancer of the lining of the uterus predominately affects post-menopausal women aged 
between 55 and 70 years, with a few cases occurring before age 40. The incidence of 
endometrial cancer has been reported to be 44 in 100,000 and is constantly rising as 
life expectancy increases (Executive, NHS 1999; Jemal et al 2009). It was the cause 
of 1,741 deaths in the UK in 2008 (Cancer research UK). The rise continues to place a 
financial burden on the NHS. Annual costs for gynaecological cancer surgeries are 
estimated to double on average (average rise of almost £200,00). Increased 
endometrial cancer referral to Cancer Centers are estimates to increase annual costs 
for surgery by about 90% (range: £0 to £120,00). (Executive, NHS 1999). 
 
The most important risk factors for endometrial cancer are postmenopausal status, 
body mass index >25kg/m2, hyperoestrogenism (for example, nulliparity/infertility, 
anovulation, late onset menopause) and unopposed exogenous oestrogen use, for 
example tamoxifen. In premenopausal women, obesity can cause insulin resistance, 
ovarian androgen excess, anovulation, and chronic progesterone deficiency 
(Masciullo et al 2010). In postmenopausal women, the conversion of androgens to 
oestrogen is enhanced in peripheral fat stores (Masciullo et al 2010). Considering the 
challenges we face in tackling obesity in our population, it though to be an 
increasingly common risk factor responsible for the development of endometrial 
cancer. 
 
Half of patients diagnosed with endometrial cancer have identifiable risk factors, 
while the other half appear to be at low risk (Masciullo et al 2010, Amant et al 2005). 
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This highlights the importance of early detection and surveillance. The primary 
presenting symptom patients develop is an abnormal bleeding pattern, either post-
menopausal or inter-menstrual bleeding. This can allow for early detection of the 
cancer, and by laying a good management plan, improve the survival rates. Although 
the 5-year survival is good for stage I & II, it is only 45% and 25% for stages III & IV, 
respectively (Abeler & Kjorstad 1991; Morrow et al 1991; Grigsby et al 1992). The 
survival rates for advanced endometrial cancer are worse than other common 
gynaecological cancers, such as ovarian cancer. 
 
Bokhman (1983) broadly categorised endometrial cancer into two groups: estrogen-
dependent endometrioid endometrial carcinomas (EECs), or Type 1, and non-
endometrioid endometrial carcinomas (NEECs), or Type 2 tumours. These groups can 
be further sub-divided with variants of Type 1 endometrioid adenocarcinoma (See 
Table 1). Cancers are grouped depending on histopathology, epidemiology, and 
clinical behaviour. (Saso et al 2011; Okuda et al 2010). 
Table 1: Endometrial cancer types 
Type 1 Type 2 
Endometrioid endometrial 
adenocarcinoma: 
- With squamous differentiation 
- Villoglandular 
- Secretory 
- With ciliated cells 
- Mucinous carcinoma 
 
Non-endometrioid carcinoma: 
- Serous carcinoma 
- Clear-cell carcinoma 
- Mixed carcinoma 
- Squamous-cell carcinoma 
- Transitional- cell carcinoma 
- Small-cell carcinoma 
- Undifferentiated carcinoma. 
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Approximately 70-80% of diagnosed endometrial carcinomas are classified as EEC 
Type 1 (Okuda et al 2010). EECs arise from atypical complex hyperplasia and are 
largely oestrogen driven, which exhibit low histological grade and therefore a 
favourable prognosis. Since the oestrogen responsiveness of the endometrial cells are 
mediated via oestrogen receptors and more differentiated cells possess steroid 
receptors, it is believed that more differentiated cancers are hormone responsive 
(hence less aggressive). The rare mucinous carcinomas are also considered Type 1 
carcinomas because they are of low histological grade and usually express oestrogen 
and/or progesterone receptors (Samarnthai et al 2010). 
On the other hand prognosis is poor with Type 2 NEECs, which are rare, occurring in 
approximately 20-30% of all women diagnosed with endometrial cancer (Okuda et al 
2010). Women with Type 2 endometrial cancer, predominately high grade serous and 
clear-cell carcinomas are not related to the oestrogen pathway and arise in the 
environment of an atrophic endometrium (Prat et al 2007; Okuda et al 2010; 
Potischman et al 1996). They are at a higher risk of relapse and they develop 
metastatic disease due to the aggressive nature of the cancer (Amant et al 2005).  
It is important to note that grouping of cancers is not strict, as there is an increasing 
incident of endometrial cancers with shared group type characteristics. For example, 
mixed serous and endometrioid tumours. There is uncertainty on how these variants 
of cancers develop and how they may progress, therefore creating issues over their 
classification. Along with the mixed variants, there is confusion over carcinosarcomas 
(malignant mixed mullerian tumours, or MMMTs) as they are currently excluded 
from the uterine sarcoma and classified as metaplastic carcinomas (D’Angelo & Prat 
2010). MMMTs account for 1-2% of all uterine corpus malignancies (Lax 2007). 
Endometrial carcinomas and MMMTs have distinct molecular genetic pathways and 
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exhibit different biological features, however, MMMTs epithelial component can 
resemble high grade endometrioid, serous or clear cell carcinoma. In light of this, 
many studies classify carcinosarcomas as NEECs (Lax 2007; Okuda et al 2010, 
Kernochan & Garcia 2009).  
Whether it is by understanding the underlying genetic changes in tumour development 
and progression or examining the clinical and pathological features of the several 
types of endometrial cancer; further studies on endometrial cancer classification are 
required.  
Endometrial cancer is largely diagnosed histologically from endometrial tissue 
obtained from a pipelle or other forms of endometrial biopsy. A systematic 
quantitative review and a meta-analysis evaluating the accuracy of pipelle biopsies for 
the diagnosis of endometrial cancers and atypical hyperplasia showed it to be 81-99% 
sensitive and 98% specific (Dijkhuizen et al 2000; Clark et al 2002). Transvaginal 
ultrasound can also be used to identify symptomatic women who may have a 
diagnosis of endometrial cancer, identifying a thickened and irregular endometrial 
lining which may be associated with the growth of endometrial cancer cells.  
All diagnosed cancers are staged surgically or from clinical findings and scans. 
International Federation of Gynecology and Obstetrics (FIGO) recently developed a 
new staging scheme for endometrial cancers. It incorporates depth of myometrial 
invasion and extra-uterine metastatic disease (Saso et al 2011). See Table 2. 
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Table 2: FIGO staging of endometrial cancer 
FIGO Stage Description 
Stage IA Tumour confined to the uterus, no or < ! myometrial invasion 
Stage IB Tumour confined to the uterus, > ! myometrial invasion 
Stage II Cervical stromal invasion, but not beyond the uterus 
Stage IIIA Tumour invading serosa or adnexa 
Stage IIIB Vaginal and/or parametrial metastasis 
Stage IIIC1 Metastasis to pelvic lymph nodes 
Stage IIIC2 Metastasis to pelvic and para-aortic lymph nodes 
Stage IVA Tumour invasion of the bladder and/or bowel mucosa 
Stage IVB Distant metastasis including abdominal and/or inguinal lymph nodes 
 
Histological grading only applies to endometrioid endometrial adenocarcinomas, 
other non-endometrioid carcinomas including serous and clear-cell are automatically 
classed as grade 3. Cancer is classed as low or high grade by the assessment of the 
percentage of solid growth, pattern if invasion and presence of tumour necrosis 
(Amant et al 2005). According to FIGO histological differentiation of endometrioid 
cancer is as follows (Table 3): 
Table 3: FIGO grading of endometrial cancer 
FIGO Grade Description 
Grade 1 < 5% of solid/non-glandular areas 
Grade 2 6-50% of solid/non-glandular areas 
Grade 3 > 50% of solid/non-glandular areas 
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The differentiation of endometrial cancers is one of the most important prognostic 
factors. Grade 1, 2, and 3 tumors make up approximately 45%, 35%, and 20%, 
respectively, of adenocarcinomas of the endometrium. The 5-year survival rate of 
clinical stage I cancers is 94%, 88%, and 79% for grade 1, 2, and 3 tumors, 
respectively. (Chiang JW, E Medicine).  
 
Less histological differentiation is associated with a higher incidence of deep (ie, 
greater than one half) myometrial invasion and lymph node metastases. Subsequently, 
the depth of myometrial invasion and presence of tumor in the lymph nodes is directly 
related to recurrence rates and 5-year survival rates. (Chiang JW, E Medicine) 
 
Primary treatment for advanced metastatic disease is surgery whereas radio- or 
chemotherapy is offered subsequently. Improving the current understanding of the 
metastatic process may not only provide new target for improved therapeutic success 
but will also provide means of acquiring additional diagnostic information on the 
metastatic potential of the cancer at the first diagnosis of endometrial cancer to plan 
more focused treatment. 
 
 
 
 
 
 
! ((!
1.3 METASTASIS !
 
Metastasis is a cascade of linked steps involving cancerous cells, originating from a 
primary tumour with the ability to invade surrounding tissue and disseminate to 
distance ectopic sites (Mendoza & Khanna 2009; Liotta & Stetler-Stevenson 1991). 
This is quite a common process that occurs in many cancers in their advanced stage. 
The distant spread and invasion (metastasis) of cancerous endometrial cells beyond 
the uterine cavity contributes to the advanced disease and is the reason for death in 
endometrial cancer. This is despite the significant improvements in diagnosis, surgical 
techniques and general patient care.  
 
Various chemokines, proteins, enzymes, immune cells etc are implicated in cancer 
metastasis, yet the exact mechanism of this spread at a cellular level is poorly 
understood. Understanding the pathogenesis of metastasis on the systemic, cellular 
and molecular levels are important goals of cancer research. 
 
There have been many theories and hypotheses made explaining this complex and 
intricate process. The “seed and soil” hypothesis is a well-known theory first 
described by Stephen Paget in 1889, suggesting that metastasis relies on interaction 
between selected cancer cells (the seeds) and specific organ microenvironments (the 
soil).  
 
Definition of the seed and soil hypothesis consists of three principles: 
1. Primary neoplasms (and metastases) consist of both tumour cells and host 
cells. Host cells include epithelial cells, fibroblasts, endothelial cells and 
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infiltrating leukocytes. Moreover, neoplasms are biologically heterogeneous 
and contain genotypically and phenotypically diverse subpopulations of 
tumour cells, each of which have the potential to complete some steps in the 
metastatic process, but not all.  
 
2. Process of metastasis is selective for cells that succeed in: 
a. Invasion 
b. Embolization 
c. Survival in the circulation 
d. Arrest in a distant capillary bed 
e. Extravasation into the organ parenchyma 
f. Multiplication within the organ parenchyma 
 
3. Metastases can only develop in specific organs. The microenvironments of 
different organs (the soil) are biologically unique. Outcome of metastasis 
depends on multiple interactions (cross-talk) of metastasizing cells with 
homeostatic mechanisms, which the tumour cells can usurp. Therapy of 
metastases, therefore, should be targeted not only against the homeostatic 
factors that promote tumour-cell growth, survival, angiogenesis, invasion and 
metastasis.  
 
 
James Ewing challenged this theory in the 1920’s proposing that the circulatory 
system was primarily responsible for the organ-specific metastatic dissemination. 
Both have been shown to be equally important and interlinked over time as research 
in this field expands. 
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Weiss and Sugarbaker concluded regional metastasis involved anatomical or 
mechanical considerations, such as efferent venous circulation or lymphatic drainage 
to regional nodes. On the other hand distant metastasis were site specific. The 
distribution of metastatic lesions is largely dependant on mechanical factors, e.g. 
arrest of emboli in capillaries of secondary organs, therefore suggesting both 
mechanical and the ‘soil’ factors are required for metastasis to occur. 
 
The main sites of metastasis are liver, lung, peritoneum and bone, the occurrence of 
which depends on the primary location of the cancer. Spread of endometrial cancer 
cells originating from the lining of the uterus initially migrate and penetrate into the 
myometrium. At this stage it becomes more likely to spread to local areas via the 
lymphatic system, beginning with malignant cells infiltrating local pelvic, paraaortic 
and inguinal lymph glands (Morrison et al 2009). The cancer can grow into the 
fallopian tubes, cervix and vagina, or further beyond into the bladder or rectum. In 
advance, late stage malignancy cancer cells can penetrate through the outer lining of 
the uterus (serosa) and spread into the abdomen and affecting the peritoneum. 
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1.4 METASTASIS INDUCING PROTEINS (MIPs) !
 
Endometrial cancer is an oestrogen dependent disease. In breast carcinoma, which is 
also an oestrogen dependent disease, expression of a panel of proteins predict the 
survival and that they were shown to be involved in metastasis (Wang et al 2006; 
Tuck & Chambers 2001; Rodrigues et al 2007, De Silva Rudland et al 2006; Rudland 
et al 2000; Jenkinson et al 2004; Fritzsche et al 2006; Innes et al 2006; Liu et al 2005). 
These proteins are called metastasis inducing proteins (MIPs) and include S100P, 
S100A4, Osteopontin (OPN) and Anterior gradient homolog 2 (AGR2). The work 
carried out included in this thesis proposed to investigate if there are similarities in the 
expression of these proteins in endometrial cancer, and if there is a correlation 
between FIGO cancer grading and the expression of the MIPs suggesting that they 
may play a similar role as in breast cancer.  
 
1.4.a INVOLVEMENT OF MIPs IN ENDOMETRIAL CANCER  
 
To the best of my knowledge, there are only a few studies exploring the metastatic 
process in endometrial cancer.  Five publications have suggested that OPN and 
S100A4 are expressed by primary and cell line endometrial cancer cells (Du et al 
2009; Cho et al 2009; Hashiguchi et al 2006; Xie et al 2009; Xie et al 2007). 
However, the expression of the other two MIPs, namely S100P and AGR2 has yet to 
be explored in human endometrial cancer. 
 
A study by Du et al (2009) showed an over-expression of OPN in a human 
endometrial cancer cell line Ishikawa, (ISK) and in tumour-associated human 
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endometrial endothelial cells (HEECs) isolated from tissue samples of a patient with 
endometrial cancer. They conducted a follow up study using the short interference 
RNA (siRNA) method to silence the OPN gene in HEECs and ISK cells. Knocking 
down OPN gene reduced the cell migration and invasiveness of these cancer cells in 
vitro. In a mouse model of tumourigenesis they demonstrated that and decreased 
invasiveness in both HEECs and ISK compared to normal controls. Furthermore, ISK 
cells transfected with OPN siRNA formed a smaller tumour in a mouse model of 
tumourigenesis compared to the scrambled siRNA controls. This data suggested an 
important role of OPN in endometrial cancer-growth and associated angiogenesis. 
(Du et al 2009).  
 
Cho HB et al (2009) using real-time polymerase chain reaction and 
immunohistochemistry evaluated the role of OPN as a potential biomarker in 
endometrial cancer. Expression of OPN was first analysed in endometrial cancer cell 
lines and endometrial cancer tissue, both of which showed an over expression of OPN 
compared to normal endometrium.  Plasma OPN levels were measured, showing a 
significantly higher preoperative level of OPN in endometrial cancer patients than in 
healthy controls. Patients were also followed up and monitored for survival and 
recurrence (mean time 22.1 months), which displayed that the overall survival and 
disease-free survival rates for OPN positive patients were significantly lower than the 
survival rates of OPN negative patients. These results have demonstrated the potential 
value of plasma OPN as a useful diagnostic marker for endometrial cancer (Cho et al 
2009).  
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Approximately 10% of patients with ovarian cancer develop endometrial cancer 
synchronously, and 5% vice versa (Chiang et al 2008). Herrinton et al (2001) 
suggested that these tumours may be mechanistically linked to reproductive 
hormones. However, it is unclear whether this is in relation to primary tumours or to 
metastasis from the ovary to the endometrial tumour or vice versa (Soliman et al 
2004, Zaino et al 2001). Most ovarian tumours are derived from the surface 
epithelium of the ovary and are adenocarcinomas of different histological subtypes, 
manifesting in various morphological forms as (cyst) adenocarcinomas with serous, 
mucinous, clear-cell, or endometrioid differentiations (Hemminki et al 2003, Young 
& Scully 2002). As discussed in Chapter 1.2, primary endometrial neoplasms also 
include the same subtypes as Type 1 or Type 2 endometrial carcinomas. Van Niekerk 
et al (2009) carried out a study investigating the association between primary 
endometrioid carcinoma of the ovary and synchronous malignancy of the 
endometrium. Their results indicated that in 2.9% of patients diagnosed with 
epithelial ovarian malignancy a second new primary malignant tumour is occurring in 
the endometrium, especially women diagnosed with an endometrioid histological 
subtype.  
 
In a study comparing OPN expression at DNA, RNA and protein levels of 
endometrioid endometrial cancer and ovarian endometrioid cancer tissue, OPN 
expression was seen in 50% (15/30) of the endometrioid endometrial cancers.  There 
was no significant difference observed in the percentage of positive cytoplasmic OPN 
staining between the ovarian and endometrial cancer cells. Ovarian endometrioid 
cancer is known to resemble endometrioid endometrial cancer morphologically, 
however, they behave different biologically (Zwart et al 1998). This study aimed to 
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investigate whether the different behaviours of the cancers could be explained by 
OPN expression, but this hypothesis could not be accepted (Hashiguchi et al 2006).   
 
Comparison between the behaviour of ovarian and endometrial cancers, in light of 
their morphological similarities is an interesting area of research. Hashiguchi et al 
(2006) broached the idea of OPN involvement in the association between the two 
cancers. This should hopefully stimulate further molecular studies into the possibly 
carcinogenic pathways and widen our knowledge on the role of OPN and the other 
MIPs.  
 
Both studies examining the role of S100A4 in endometrial cancer showed an over-
expression of S100A4 in high-grade and advanced stage endometrial carcinomas. Xie 
et al (2009) down-regulated S100A4 expression in endometrial cancer cell line, which 
resulted in undetectable S100A4 protein level and significantly decreased migration 
and invasion. Both studies showed the important relevance and role of S100A4 in 
endometrial cancer, especially in advanced stage cancer where the chance of 
developing metastasis is high. This may suggest that S100A4 plays a vital role in the 
metastasis of endometrial cancer.   
 
A recent study has shown that these proteins are cyclically expressed in the normal 
human endometrium and are aberrantly expressed in women with endometriosis, 
which is a benign metastatic disease (Hapangama et al 2011 (In press)). This gives us 
a good basis to further examine whether endometrial cancer is associated with 
abnormal expression of MIPs and weather MIPs are associated with advanced disease, 
and decrease survival.   
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1.4.a.i  OSTEOPONTIN 
 
Osteopontin has been found to be produced by epithelial cells of the gastrointestinal, 
urinary and reproductive tracts, the gall bladder, pancreas, lung bronchi, lactating 
breast, salivary glands and sweat ducts (Rodrigues et al 2007).  
Senger was first to describe Osteopontin as a glycol-phosphoprotein that is expressed 
by numerous human malignant epithelial cells in 1979 (Senger et al 1979).  OPN gene 
has been mapped to chromosome 4q13 in humans, and along with its associated 
isoforms the molecular weight is measured to be between 41-75 kDA. It is also know 
to be expressed at high levels by T-lymphocytes, epidermal cells, bone cells, 
macrophages, and endothelial cells (Wai & Kuo 2004; Chakraborty et al 2006).  
Various investigators have examined the functional role of osteopontin further, to 
reveal that it functions by mediating cell-matrix interactions and cellular signaling 
through binding with intregrin and CD44 receptors. OPN facilitates cell adhesion, 
chemotaxis, stress-dependent angiogenesis, prevention of apoptosis, and anchorage-
independent growth of tumor cells.  
OPN is a ligand for several integrins, especially integrin "v#3, and since integrins are 
involved in cell-cell adhesion and anchorage, it is not surprising that integrin "v#3 and 
OPN have been detected in breast cancer bone-metastases. This OPN:"v#3 interaction 
directly mediates migration and invasion of tumor cells, and induces 
neovascularization by up-regulating endothelial cell migration, survival, and lumen 
formation during angiogenesis. OPN also facilitates cell-matrix and cell-cell 
interactions by the interaction via CD44 glycoproteins which are universally 
expressed cell-surface adhesion molecules. 
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Recent studies have provided substantial evidence to link OPN with the regulation of 
metastasis, by establishing a correlation between high levels of OPN expression and 
malignant invasion in various cancers, including breast, stomach, lung, prostate, liver 
and colon (Shevde et al 2010; El-Tanani et al 2006; Furger et al 2001).  
 
1.4.a.ii  S100P 
 
S100P was found to be up regulated during the implantation window in the human 
endometrium (Tong et al 2010). However, the role that S100P plays in the 
implantation window is still unclear. Most S100 proteins are thought to mediate 
regulatory functions by binding to and modulating the biological activity of 
intracellular compounds (Tong et al 2010). 
S100P is a 95-amino acid member of the large S100 family, small calcium binding 
proteins with intracellular or extracelluar functions. Becker et al (1992) founded the 
protein, which was purified and characterized from the placenta, designating the ‘P”.  
S100 was denoted to identify a group of proteins soluble in a 100% saturated 
ammonium sulfate solution (Moore 1965). While all S100 genes are localized on 
human chromosome 1, the gene for S100P is exclusively located on human 
chromosome 4q16. (Schafer et al 1995). 
There is increasing evidence suggesting that S100P has a significant role in cancer. 
This gene has been found to be expressed in several cancers, including pancreas, 
colon, prostate, and lung. It has also been shown to be associated with poor clinical 
outcome. (Logsdon et al 2003, Guerreiro Da Silva et al 2000, Wang et al 2006, 
Fuentes et al 2007, Mousses et al 2002, Diederichs et al 2004).   
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S100P has been shown to mediate tumor growth, drug resistance, and metastasis. 
Therefore, S100P is a useful marker for differentiating cancer cells from normal cells 
and can aid in the diagnosis of diagnosis by cytological examination.  
Studies in breast cancer, an oestrogen dependent cancer like endometrial cancer, have 
shown there to be a link between expression of S100P and progression of breast 
cancer (Guerreiro Da Silva et al 2000).  There has also been evidence to support the 
role of S100P as an inducer of breast cancer metastasis.  
There is no research investigating the expression of S100P in endometrial cancer, but 
it has been hypothesized that endometrial cancer will have a similar expression of 
S100P to breast cancer as they are both oestrogen dependent cancers. 
The primary mechanism of action of S100P, at least in the case of pancreatic and 
colon cancer, is through the activation of the cell surface receptor RAGE (Receptor 
for advanced glycation end products). (Arumugam et al 2010). RAGE can be 
activated by a number of ligands, including advanced glycation end products, specific 
S100 molecules (S100B, S100A12, and S100P), amyloid, and amphoterin (Logsdon 
et al 2007; Sparvero et al 2009). RAGE participates in a number of important 
pathological processed besides cancer, including Alzheimer’s diseases, diabetes, and 
inflammation (Logsdon et al 2007; Sparvero et al 2009).  
Activation of RAGE by S100P stimulates cellular signaling pathways, including the 
mitogen-activated protein (MAP) kinase and nuclear factor-B (NFkB) pathways. 
NFkB signaling may be of particular importance, because elevated NFkB activity is 
associated with increased resistance to therapies in different cancers, Therefore, 
interventions that block the ability of S100P to activate RAGE may provide 
therapeutic benefit.  
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1.4.a.iii ANTERIOR GRADIENT 2 
 
Anterior gradient homolog 2 (AGR2) was first described in Xenopuslaevis embryos, 
as it played an important role in inducing the formation of the forebrain and the 
mucus secreting cement gland. It was then identified in humans, during the 
investigation focused on differentially expressed genes in oestrogen receptor-positive 
breast cancers (Wang et al 2008). 
The first study reporting the expression of AGR2 in human endometrium arises from 
our laboratory (Hapangama et al 2011). A cyclical variation in the expression of 
AGR2 in the normal fertile control samples and increased expression of AGR2 in 
endometriosis samples was observed.  Endometriosis is a benign metastatic disease, 
which has similar properties and functions as cancerous metastasis. This provides us 
with a foundation to hypothesis that AGR2 would be over-expressed in endometrial 
cancer.  
It is an oestrogen and androgen responsive protein, up regulated in a number of 
cancers, including breast, lung, ovarian, gastric, pancreatic, oesophageal, and prostate. 
Its expression in all premalignant and malignant oesophageal adenocarcinoma 
suggests that it serves an important role in disease pathogenesis (Wang et al 2008). 
Extensive research has been carried out investigating the role of AGR2 in breast 
cancer tissue and cell lines (Fritzsche et al 2006; Innes et al 2006; Liu et al 
2005;Wang et al 2008). Endometrial cancer is also an oestrogen dependent disease, 
like breast cancer, therefore AGR2 may express abundantly in endometrial cancer.  
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1.4.a.iv S100A4 
 
There are now over twenty S100 family members that are localised to specific tissue 
in humans, a multi-gene family of calcium binding proteins of the EF-hand type.   
S100A4 gene in humans is located in the region of chromosome 1q21, which is 
frequently rearranged in a number of malignancies, including endometrial cancer.  
Several investigators cloned the S100A4 gene, identifying the protein as a highly 
expressed transcript in growth-stimulated cultured cells, metastatic tumor cell lines 
and during morphogenic conversion from an epithelial to mesenchymal phenotype. In 
addition, during oncogenic transformation S100A4 expression levels are up regulated 
(Garrett et al 2006; Helfman et al 2005; Xie et al 2009). 
The association between S100A4 and metastatic capacity was first introduced by 
Ebralidze et al in 1989. Since then S100A4 has been categorized as a metastasis 
associated protein and a regulator of tumor progression, with significant over-
expression seen in breast, pancreatic, prostate, gallbladder, esophageal, gastric, lung, 
and thyroid carcinomas in comparison with its normal tissue (Garrett et al 2006; 
Rudland et al 2000).  
Studies to determine the function of S100A4 have shown that it may play a role in the 
different aspects of tumor progression, including motility, invasion, and apoptosis. It 
has been proposed that S100A4 affects motility through its interaction with a non-
muscle myosin.  It is also involved in a variety of cellular processes, such as immune 
response, differentiation, cell growth etc (Ismail et al 2010; Sherbe 2009; Tarabykina 
et al 2007; Zhang et al 2005). 
S100A4 has also been coined to be a prognostic marker in a number of cancers, as 
expression of S100A4 is highly correlated with patient death. The universality of 
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S100A4 expression in a variety of cancers illustrates the potential use of S100A4 as a 
marker for tumor metastasis and disease progression (Garrett et al 2006), which 
hopefully can be applied for endometrial cancer. 
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1.5 HYPOTHESES 
 
 
Since the four MIPs have shown to be involved in the metastatic process of breast 
cancer, studies are under way to investigate if they would be suitable therapeutic 
targets to prevent distant spread of breast cancer. Therefore, it is important that we 
assess the involvement of the same proteins in endometrial carcinogenesis and 
metastasis as the advances in treatment of breast cancer can then hopefully be 
exploited in the treatment of endometrial cancer as well.  
With the literature to date on endometrial cancer and MIPs we propose the following: 
 
1. The literature in breast cancer studies suggests that MIPs are expressed in 
breast cancer cells. Breast cancer and endometrial cancer, in particular Type 1 
endometrioid adenocarcinomas are both oestrogen dependent diseases. 
Therefore we hypothesise that the four metastasis-inducing proteins AGR-2, 
S100A4, S100P, Osteopontin are expressed in endometrial cancer cells.  
 
2. Since the oestrogen dependence of various endometrial cancer types are 
different, we hypothesise that there is differential MIPs expression in these 
tumour types. 
 
3. Higher the grade and wide spread cancer, increases the risk of metastatic 
disease, therefore we hypothesise that high-grade endometrial cancers e.g. 
Type 2 cancers, have an increased expression of the MIPs in comparison to 
low-grade tumours 
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2 METHODS !!
 
Samples used in this study were obtained from human subjects. A vast number of 
ethical issues arise from collecting human samples for the purpose of research. These 
were all taken in consideration and appropriate ethical approval was sought from the 
adult local research ethics committee in Liverpool before commencing the study. We 
collected samples on two different ethically approved projects. Control samples, 
normal fertile and postmenopausal endometrium were collected under “Endometrial 
stem cell study” ethics (09/H1005/55). Endometrial cancer samples, and few 
postmenopausal control samples were collected under “MIPs in endometrial cancer 
study” ethics (11/H1005/4). [Refer to Appendix 7.1 & 7.2 for consent forms and 
patients information leaflets for each ethics]. 
 
 
2.1 PATIENT RECRUITMENT 
 
 
Patients were recruited from the Liverpool Women’s Hospital. Consent from patients 
was obtained by a trained member of the research team or by doctors from the 
Liverpool Women’s Hospital.  
We employed a strict inclusion and exclusion criteria in order to recruit necessary 
patients for the study. (See Tables 4 & 5).  
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Table 4: Principle inclusion criteria 
Study Group Women with a histological diagnosis of endometrial cancer, 
undergoing surgical treatment. 
Normal 
Control Group 
A) Normal ovulating, fertile women in the proliferative phase 
of their menstrual cycle, undergoing surgical procedure for 
benign conditions (e.g. laparoscopic sterilization). 
B) Post-menopausal women undergoing hysterectomy with 
NO history of abnormal bleeding. 
 
Table 5: Principal exclusion criteria 
Study Group History of other gynecological cancers (cervical, ovarian etc). 
Normal 
Control Group 
• Women in either the menstruation or secretory phase of 
their menstrual cycle.  
• History of abnormal vaginal bleeding. 
• Women who have take hormonal contraceptives over 
preceding three months, including with an intra-uterine 
contraceptive device. 
• Women currently breast feeding or pregnant. 
• History of infertility or recurrent pregnancy loss. 
• History of endometriosis. 
 
Patients who fit the above criteria and scheduled for surgery were approached on the 
day of the operation and informed of the study. They were given a patient information 
leaflet, explaining the reasons for the study, their involvement and contact details.  
Patients who chose to consent to having an endometrial biopsy and blood sample 
taken were asked to sign a consent form. Two copies of the consent form were taken, 
one kept in the patient’s notes and the other, secure in the research department with 
the sample and blood processing paper work. 
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Additional clinical information was gained from the patient and their notes, including 
(Table 6): 
Table 6: Patient demographic data 
General • Age 
• Weight, height & BMI 
• Smoker/Non-smoker 
• Last menstrual period/Beginning of menopause 
• Cycle length 
• Gravida/Parity 
• Relevant past medical history, e.g. Hypertension, 
Diabetes mellitus 
• Relevant gynecological history, e.g. Gynae 
malignancies or operations 
Endometrial Cancer 
Patients 
• Histological diagnosis 
• Staging of the cancer 
• Presenting complaint 
• Treatment plan (Chemotherapy/Radiotherapy) 
 !!
2.2  ENDOMETRIAL SAMPLE COLLECTION AND  
 PROCESSING 
 
 
No extra surgical procedures were carried out over and above which was clinically 
indicated in any women in the study. Either a pipelle sample or full thickness sample 
was obtained from patients during theatre.  
Endometrium was obtained using a pipelle from women who were not having a 
hysterectomy. Trained members of the research team or the surgeons obtained pipelle 
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samples from the uterus in situ prior to the plan procedure. Pipelle sampling is a 
routine procedure undertaken in day clinics and usually not under anesthetic. A 
pipelle is a flexible plastic tube that allows a sample of endometrium to be obtained. 
In theatre, the patient was prepped and sterilised for their planned surgery as normal. 
The pipelle was removed from its sterile packaging and carefully inserted through the 
cervical canal into the uterus, following which the pipelle’s plunger was withdrawn. 
Whilst rotating and gently inserting the pipelle in and out of the uterine cavity an 
adequate amount of tissue from the endometrium should be suctioned out.   
Full thickness endometrial samples were obtained from patients having a 
hysterectomy. Shortly after the uterus was removed, orientation of the uterus was 
determined and placed on its anterior side. Using a carbon steel surgical blade, a 
median incision on the posterior side was carefully made from the fundus to the 
cervical canal. Deeper incisions were made to expose the uterine cavity adequately. 
Once the endometrium was identified, a curved lateral incision was made along side 
the endometrium. At either ends of this incision, two further incisions were made at 
90 degrees through the myometrium to dissect out a full thickness sample.  
The endometrial biopsies collected were divided into four. The first part was frozen 
immediately for protein/RNA extraction, the second was placed in neutral buffered 
formalin (NBF) for paraffin sections, the third in collection media for culturing, and 
the final part in RNA later for RNA extraction (Refer to SOP in appendix 7.3a). 
 
2.2.a FROZEN SAMPLES 
 
Extracted endometrium was immersed into phosphate buffered saline (PBS) to 
remove excess blood from the sample, to ensure only tissue is frozen. The sample was 
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transferred to the laboratory and placed on dry ice during the preparation time under 
the fume hood. Using forceps the entire sample was transferred onto a disposable 
plastic container. All viable tissue was then carefully placed into a cyrotube, labeled 
with the sample ID and date and stored in a -70°C freezer.  
 
2.2.b PARAFFIN SAMPLES 
 
In order to obtain paraffin sections of samples, one part of the endometrial sample 
was directly placed in 10% NBF solution and incubated for a minimum 24 hours at 
room temperature. NBF is a special fixative solution that preserves the tissue and cells, 
as they are normally found in situ and causes the cross linking of proteins.  
Samples are further embedded in wax to allow thin sections of the sample to be cut. 
This was achieved by processing the samples through a well-cycled program 
incubating them in increasing concentrations of alcohol from 60% to 100%, xylene 
and finally hot paraffin wax. These steps ensured the removal of water within the 
tissue, and subsequently replaced with paraffin wax. Once processed the sample was 
embedded in liquid paraffin using the embedding machine, allowed to set and stored 
in the fridge at -4°C. Embedding samples in paraffin maintains the natural shape and 
architecture of the sample during long term storage and sectioning. (See SOP in 
appendix 7.3c & 7.3d)  
 
2.2.c CULTURE SAMPLES 
 
A section of all the endometrial samples collected was immersed in collection media, 
so an attempt could be made to culture and grow the cells. The collection media 
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provides the cells with the perfect environment and essential nutrients to adequately 
grow and develop.  
 
2.2.d RNA LATER SAMPLES 
 
A small section of the endometrium was placed in a cyrotube containing RNA later 
solution for a minimum 24 hours at -4°C. The sample was then transferred into a fresh 
cyrotube and stored in the freezer at -70°C. 
 
 
2.3 BLOOD SAMPLE COLLECTION AND 
PROCESSING 
 
 
Blood samples were also taken from all patients. This was taken in the anaesthetic 
room prior to the surgery, from the same cannula placed by the anaesthetists to gain 
venous access. A total of 10ml of blood was taken and dispersed into blood serum and 
ethylenediaminetetraacetic acid (EDTA) collection tubes.  
The whole blood sample is directly aliquotted into to small cyrotubes. Plasma serum 
blood bottle was centrifuged and top plasma serum layer was then transferred into 
cyrotubes. Both blood samples are frozen and stored in a -70oC freezer. (See SOP in 
appendix 7.3b). 
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2.4 SECTIONING AND SLIDE PREPARATION 
 
 
After samples were processed and embedded as explained in chapter section 2.2.b, 
thin sections of the samples are required for the immunohistochemistry technique. 
Using the Microm rotary microtome (Microm Ltds, Thame, UK) the paraffin blocks 
were sectioned with a 3um thickness. The sections were carefully floated onto a pre-
heated water bath and picked up onto aminopropyl triethoxy saline (APES) coated 
microscope slides. Slides were dried overnight at room temperature before 
immunohistochemistry steps were followed. (Refer to SOP in appendix 7.3.e)  
 
2.5 LABORATORY TECHNIQUES !
 
To assess the expression of MIPs in endometrial cancer tissue techniques such as 
immunohistochemistry and RT-PCR were employed.  
 
2.5.a IMMUNOHISTOCHEMISTRY 
 
Immunohistochemistry (IHC) is a technique that uses antibodies to microscopically 
identify, localize and stain proteins (antigens) in tissue samples. A set protocol was 
discussed and created by the research team to ensure the best possible outcome. It was 
then employed to assess the expression of the four proteins (S100P, OPN, S100A4 
and AGR-2) using the Vector ImmPRESS IHC reagent kit. (See SOP in appendix 
7.3.f & 7.3.g) 
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2.5.a.i  METHOD 
  
Slides used were clearly labeled with information of the antibody tested, its conditions 
and the date. They were then baked for an hour at 60°C or overnight at 36°C to soften 
wax and ensure the tissue remains on the slide.  Paraffin wax must be completely 
removed from the slide to ensure aqueous reagents adhere and penetrate the tissue; 
this was achieved by immersing the slides in xylene for 2 x 10 minutes. Tissues 
sections were then re-hydrated through graded ethanol to water as followed: 2 x 5 
minutes in 100% ethanol, 1 minute in 70% and further minute in 60% ethanol 
followed by immersion in distilled water. 
A pH 6 0.01M citrate based solution was used in the antigen retrieval procedure and 
was achieved by pressure-cooking the sections for one minute, otherwise known as 
the heat induced epitope retrieval (HIER) method. Antigen retrieval is designed to 
unmask antigens in the paraffin embedded tissue sections by breaking protein cross-
links, which were created during paraffin fixation by NBF. This therefore enhances 
the intensity of antibody detection. The use of heat in the HIER method interrupts the 
cross-links while buffer solution aid in maintaining the break allowing the antibody to 
attach onto its paired antigen.  
Following antigen retrieval, slides were washed in tris buffered saline (TBS) for 5 
minutes, and incubated in 0.3% hydrogen peroxide/TBS for 10 minutes blocking any 
endogenous peroxidase activity in the specimen. TBS is a buffer used to maintain the 
samples pH levels between 7-9.2. Endogenous peroxidase and alkaline phosphatase 
are the endogenous enzymes found in a variety of tissues and most commonly known 
to generate false positive signals. The use of hydrogen peroxide on the samples 
increases the level of substrate hence eliminating endogenous enzyme activity. 
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Slides were washed again in TBS for 5 minutes. A DAKO hydrophobic marker pen 
was used to mark the area on the tissue section to be stained, followed by another 5 
minute TBS wash.  
Sections were incubated in a moisture chamber, to prevent the sections form drying 
out with the primary antibodies presented in table 7: 
Table 7: IHC Antibody conditions 
Antibody Concentration Duration Temperature 
Polyclonal rabbit anti-human AGR-2 
(Liu et al., 2005) 
1:100 Overnight 4˚C 
Monoclonal rabbit anti-human S100A4 
(DAKO Ltd, UK) 
1:2000 Overnight 4˚C 
Monoclonal rabbit anti-human Osteopontin 
(Developmental Studies Hybridoma Bank, Iowa City, 
IA, USA) 
1:500 2 hours Room temp. 
Monoclonal mouse anti-human S100P 
(BD Transduction Laboratories, Cowley Oxford, UK) 
1:100 2 hours Room temp. 
 
The relevant antibody dilutions were made using 0.5% bovine serum albumen (BSA). 
At higher temperatures the antigen-antibody pairing occurs quicker, therefore to 
prevent false over expression of proteins overnight incubations were stored at a lower 
temperature of 4°C. 
Prior to the application of osteopontin antibody, horse serum was applied to all 
sections selected for osteopontin staining for 20 minutes at room temperature. This is 
used to reduce background or non-specific staining.  
! FG!
Sections were then thoroughly washed in TBS twice for 5 minutes. Slides were placed 
back in the humidified chamber and incubated with secondary antibody for 30 
minutes at room temperature. Anti-rabbit biotinylated horseradish peroxidase (HRP) 
polymer was used for anti-S100A4, AGR-2 and Osteopontin and anti-mouse HRP 
polymer for S100P antibody.  
After the final two washes in TBS, sections were stained with a substrate/chromagen 
solution using ImmPRESS polymerized reporter enzyme staining system. The 
diaminobenzidine (DAB) solution was applied onto the anti-S100A4 and AGR-2 for 5 
minutes; and for 10 minutes for the anti-S100P and Osteopontin sections. All sections 
were then washed in distilled water to stop the DAB reaction and counterstained with 
filtered Gill 2 haematoxylin for a minute. Sections were dehydrated through graded 
ethanols and xylene, times as follows: 1 minute in 60% ethanol, 1 minute in 70%, 2 x 
3 minutes in 100%, 5 minutes in xylene and further 10 minutes in fresh pot of xylene. 
Coverslips were mounted over each section using DAKO faramount aqueous 
mounting medium, and left to dry before analyzing under light microscope. 
Negative controls anti-rabbit and anti-mouse IgGs were included in each staining run. 
Breast carcinoma sections were used as external positive controls for the four MIPs.  
 
2.5.a.ii  IHC ANALYSIS 
 
Immunohistochemistry was used to assess the expression of the four MIPs in 
endometrial cancer in comparison to the two control groups, normal fertile and post-
menopausal endometrium.  
Quick Score technique was used to semi-quantitatively analyse and compare the IHC 
staining for the 4 MIPs, assessing 10 high power fields per sample also taking in 
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consideration the size and integrity of each sample.  The amount of staining and the 
intensity was assessed in each area and multiplied together, obtaining a Quick Score 
value as previously described by Detre S et al (1995) and Schiessl et al (2008). An 
average of the Quick Scores for each high power field per sample were used in the 
analysis. When calculating the expression seen in glandular epithelium and luminal 
epithelium, following scoring system was used (Table 8): 
 
      Table 8: Quick Score for glandular and luminal epithelium 
Intensity Proportion of Stain (%) 
0 Absent 1 < 25% 
1 Weak 2 25 – 50 % 
2 Moderate 3 50 – 75 % 
3 Strong 4 > 75 % 
       
For the assessment of stromal staining, the numbers of stromal cells positively stained 
per high power field were counted and so the proportion of stain was altered 
accordingly (Table 9): 
        Table 9: Quick Score for stromal cells 
Intensity Cell Count 
(No. of positive 
cells/field)!
0 Absent 1 < 10 
1 Weak 2 11 – 20 
2 Moderate 3 21 – 30 
3 Strong 4 > 30 
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2.5.b REVERSE TRANSCRIPTION – POLYMERASE CHAIN 
REACTION 
 
 
2.5.b.i  INTRODUCTION !
Polymerase chain reaction (PCR) is a unique molecular biological technique used to 
amplify and reproduce defined sections of precise genetic material. It involves 
manipulating the action of a naturally occurring enzyme, Taq DNA polymerase, a 
member of a family of proteins that ensure accurate replication of all living matter. 
DNA polymerases are biological macromolecules that catalyse the formation and 
repair of DNA. In the 1980s, Kary Mullis at Cetus Corporation discovered a way to 
start and stop the action of polymerase at specific points along a single strand of DNA 
using two primers complementary to sequences at the left and right ends of the region 
of DNA to be amplified. Further experimentation led Mullis to the discovery that by 
harnessing this component of molecular reproduction technology, the target DNA 
could be exponentially amplified; otherwise known as a chain reaction, allowing 
unlimited quantities of specific DNA to be replicated.  
There are three fundamental steps involved in PCR: 
1. DENATURING (MELTING): 
Double stranded DNA samples are heated at 94-96°C to separate the two 
strands of DNA by breaking the hydrogen bonds between the two strands. For 
this study samples were denatured at 95°C for 15 minutes prior to the first 
cycle to ensure that both the template DNA and primers are separated.  
Samples were then further heated at 94°C for 15 seconds per cycle. 
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2. ANNEALING: 
Once the strands have been separated, the temperature is lowered to 50-65°C 
allowing the left and right primers to anneal (attach) to their complementary 
single strand sequences. The primers are designed to bracket the DNA region 
that is required to be amplified. The temperature of this stage depends on the 
working temperature of the primer, which is usually 5°C under the melting 
temperature. Primer binding will not occur if the temperature is set too high, 
and a lower temperature would results in non-specific binding. In this study 
samples were heated at 60°C for 45 seconds allowing the annealing of the 
primers to the single strands of DNA template to occur optimally.  
 
3. EXTENSION: 
This final step is carried out at 72°C for 1 minute, which is the ideal working 
temperature for the Taq DNA polymerase enzyme. Polymerase attaches to 
each priming site and incorporates complementary nucleotides into the single 
DNA strand (i.e. when the polymerase reads a “G” on the template strand it 
adds a “C”, likewise “A-T”, “G – C” and “T – A”). Therefore creating a copy 
of the DNA template of the region specified by the annealed primers.  
These three steps are repeated 20-40 times, the exact number of cycles depends on the 
conditions set to obtain desirable results. With one cycle each single strand of a 
double stranded DNA template has been amplified into two separate double-stranded 
DNA, which, after strand separation, are then available as a template for further 
amplification in the next cycle. This process leads to exponential amplification of the 
original DNA template (See Figure 1).  
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Figure 1: PCR Steps (Adapted from http://www.korinfo.hu/drupal/en/node/8912) 
 
Reverse transcription – polymerase chain reaction (RT-PCR) is a variant of the PCR 
technique in which RNA strands are used as the starting material. An additional step 
is performed to convert the RNA to complementary DNA (cDNA) using the enzyme 
reverse transcriptase, prior to the PCR steps as described above. This technique was 
used in this study to investigate the expression of the MIP mRNAs.  
 
2.5.b.ii   METHOD 
 
2.5.b.ii.1   RNA EXTRACTION 
 
The first step involved extraction of RNA from the endometrial tissue samples. For 
extraction of RNA from formalin-fixed, paraffin embedded (FFPE) tissue samples a 
QuickExtract FFPE RNA Extraction Kit (Epicentre Biotechnologies, Cambridge, 
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United Kingdom) was used. This kit only requires heat to ensure that RNA is 
amplified accordingly. Tissue sections were heated along with QuickExtract FFPE 
RNA Extraction Solution in a thermocycler for 30 minutes at 56°C, and then 98°C for 
2 minutes. This melted the paraffin, disrupted the cells, decreased the formalin-
induced cross-linking in the sample and degraded compounds that may inhibit 
amplification. Further DNAse treatment was undertaken on the samples to improve 
the quality of amplification and prevent DNA being amplified directly by the Taq 
DNA polymerase. This was achieved by adding RNAse-free DNAse 1 to the 
extracted RNA samples, and incubation at 37°C for 10 minutes. Finally, Stop 
Solution was added to the sample tubes and heated to 65°C for 10 minutes to 
terminate the DNAse activity.  
For extraction of total RNA from frozen tissue, cultured cells and RNA-later samples, 
a TRIzol Plus RNA Purification Kit (Invitrogen Ltd., Paisley, United Kingdom) was 
used. TRIzol Reagent is a monophasic solution of phenol, guanidine isothiocyanate, 
and other proprietary components, which facilitate the isolation of RNA. It maintains 
the integrity of the RNA, while disrupting cells and dissolving cell components, as 
well as providing an immediate and highly effective inhibition of RNAse activity 
during sample homogenization or lysis.  
Tissues and RNA-later samples were homogenized in 1mL TRIzol Reagent produce a 
cell lysate and cultured cells were directly lysed in the culture dish by adding 1mL 
TRIzol Reagent.  The resulting cell lysate was passed several times through a pipette 
tip to shear the DNA. 0.2mL of chloroform was added to the sample and the mixture 
was centrifuged at 12,000 x g for 15 minutes at 4°C to separate the solution into an 
upper aqueous phase containing the RNA and a lower phenol-containing organic 
phase. The upper aqueous phase (~ 600uL) is transferred to a new RNAse-free tube, 
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followed by the addition of an equal volume of 70% (v/v) ethanol to obtain a final 
ethanol concentration of 35% and the solution centrifuged. 
The sample was then loaded onto a PureLink RNA Mini Kit Spin Cartridge 
containing a silica-based membrane to which the RNA binds during purification. 
Loading involved transferring about 700uL of the prepared sample to a Spin Cartridge 
using a pipette and centrifuging at 12,000 x g for 15 seconds at room temperature. 
The flow-through was discarded and the Spin Cartridge was reinserted into the same 
collection tube. The above steps were repeated until the entire sample has been 
processed.  For washing and elution, 700uL Wash Buffer I was added to the Spin 
Cartridge and centrifuged at 12,000 x g for 15 seconds at room temperature. The 
flow-through was discarded with the Collection Tube and Spin Cartridge was inserted 
into a new Collection Tube. 500uL of Wash Buffer II containing ethanol was added to 
the tube and centrifuged at 12,000 x g for 15 seconds at room temperature twice, 
discarding the flow-through after centrifuging. The Spin Cartridge and Collection 
Tube was centrifuged again at 12,000 x g for 1 minute at room temperature to dry the 
membrane with attached RNA. The Collection Tube was discarded and the Spin 
Cartridge was inserted into a Recovery Tube. 30uL of Rnase-free water was added to 
the centre of the Spin Cartridge and left for 1 minute. This step was repeated twice, 
adding a total of 90uL of Rnase-free water. Finally the Spin Cartridge was centrifuged 
with the Recovery Tube for 2 minutes at 12,000 x g at room temperature. The Spin 
Cartridge was discarded, leaving the Recovery Tube, which contains the purified total 
RNA and was stored at -80°C until required.  
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2.5.b.ii.2    CALCULATING RNA CONCENTRATION 
 
The RNA concentration for each sample was measured in a cuvette using the Soft 
Max Pro 5.2 programme, on the settings:  
Wavelength: 2 
Limit 1: 260 nm 
Limit 2: 280 nm  
 
First a blank was tested (i.e. no RNA) in order to obtain a reference for the other 
samples. 60uL of distilled water, or enough to adequately cover the cuvette window, 
was added to the cuvette and placed in the machine. The Soft Max Pro 5.2 programme 
is opened and “Reference” followed by “Read” is clicked giving the result: 
 
A1 
0.000 OD  {OD = Optical density} 
0.000 OD 
 
 
RNA samples were then measured, using 2uL of total RNA and 58uL of distilled 
water, ensuring that the cuvette was thoroughly cleaned with distilled water and dried 
between testing different samples to prevent contamination. The 260/280 optical 
density ratio was calculated (Limit 1/Limit 2). A ration of >1.8 is considered 
satisfactory, but ratios below 1.8 (lowest 1.55) were allowed for this study, due to the 
limited number of samples being tested. The RNA concentration [ug/mL] for each 
sample was also calculated (OD260 x 40ug/ml x dilution value), where the dilution 
value is 60uL/2uL. Around 2-4ug of total RNA was required to be reverse 
transcribed. 
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The volume of RNA concentration is calculated like so, using the example below: 
Sample A: RNA concentration calculated as 339.6ug/ml  
Need 2ug/ml RNA of Sample A for 1st C-DNA synthesis. 
339.6ug   per 1ml/1000ul 
339.6/2    1000/169.8 
=169.8         =5.88 
    2ug     per      5.88ul  
Therefore, 5.9ul of Sample RNA is required for its 1st C-DNA synthesis 
 
2.5.b.ii.3    1ST C-DNA SYNTHESIS 
 
Total RNA was reverse transcribed using SuperScript reverse transcriptase III 
(Invitrogen Ltd., Paisley, United Kingdom in a final volume of 20ul containing PCR-
Water, OligodT (0.5ug/ul), RNA Inhibitor, Total RNA (2-4ug), 5x1st cDNA Buffer, 
0.1M DTT and 10nM dNTP mix. 
All reagents were completely dissolved, vortexed and centrifuged before pipetting and 
reactions were set up on ice using 0.5uL autoclaved PCR tubes. Autoclaved PCR 
tubes were clearly labeled with sample ID and date. The following reagents were 
added to each PCR tube in this order (Table 10): 
Table 10: Solutions and amounts used for 1st step of 1st cDNA synthesis 
Solutions Sample 1 
(ul) 
Sample 2 
(ul) 
Sample 3 
(ul) 
PCR-H20 x x x 
OligodT (0.5ug/ul) 1 1 1 
RNAse inhibitor 0.5 0.5 0.5 
Total RNA (~2ug) Y Y Y 
Total Volume 9 9 9 
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OligodT and RNAse Inhibitor volumes are fixed and total RNA volume (Y) is 
obtained from the calculation above. To get the total volume of 9ul, PCR-H20 volume 
(X) was altered accordingly. 
All tubes were vortexed and centrifuged for 1 minute. They were then placed in the 
PCR machine, and heated at 70°C for 10 minutes. Samples were then cooled on ice 
and centrifuged.  
A master mix of the following solutions was prepared: [For Y reactions, prepare 
(Y+1) master mix]. (See Table 11) 
   Table 11:Master mix solutions & calculation for 2nd step of 1st cDNA synthesis 
Solutions 1x Reaction 
(ul) 
>3 Reactions [Y+1] 
(ul) 
PCR-H20 3 3x [y+1] 
5x1st cDNA Buffer 4 4x [y+1] 
0.1M DTT 2 2x [y+1] 
10mM dNTP mix 1 1x [y+1] 
Total Volume 10 10 x [y+1] 
 
Master mix was well mixed by vortexing and centrifuged, before aliquotting 10ul of 
solution to each sample tube. Finally 1ul of mmLV-RT superscript reverse 
transcriptase was added to each of the tube to get a total volume of 20ul in each tube. 
All tubes are vortexed and centrifuged and placed in the PCR machine. Samples were 
incubated at 50°C for 1 hour and again for 15 minutes at 70°C. 1st strand cDNA 
reaction mixtures were then stored at  -20°C until required for the PCR  reactions.  
 !!
! GG!
2.5.b.ii.4    PCR 
 
The first-strand cDNA reaction mixture (1 ul) was amplified by PCR with Taq DNA 
polymerase (Qiagen) as previously described (Liu et al., 2005).  
Solutions used: PCR-Water, AGR-2, S100A4, OPN & S100P 5’ and 3’-
Primers, Qiagen Taq DNA polymerase mix (5xQ Solution, 10xPCR buffer, 
dNTPmix, polymerase, [with addition DMSO for OPN and S100P]). 
New 0.5ul autoclaved PCR tubes were labeled with the sample ID and date. A total 
volume of 10ul, 1:10 dilution of 1st the cDNA-containing solution was made. 
Solutions were heated at 98°C for 10 minutes in the thermal cycler, followed by 
placing on ice for two minutes and centrifuged. 
A master mix of the relevant primers were made and added to the mix (table 12): 
Table 12: Primer master mix calculation used for PCR reaction 
Solution 1x Reaction (ul) >3x Reaction (ul) [y+1] 
PCR-H20 13 13x [y+1] 
5’-Primer 1 1x [y+1] 
3’-Primer 1 1x [y+1] 
Total Volume 15 15 [y+1] 
 
The master mix primer solution was mixed, centrifuged briefly and 15uL was 
aliquoted to each sample tube.  Finally 25ul of the Qiagen PCR master mix (2x) was 
added to each tube. All samples were vortexed, centrifuged and placed in the thermal 
cycler to be heated using the programme: 
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950C – 15mins 
 
940C – 30secs 
600C – 45secs               26 cycles                   
720C – 1min 
 
700C – 10mins 
40C – Hold 
 
 
GenBank accession numbers, primer position and sequence, and product sizes are 
presented in table 13 below. Human glyceraldehyde-3-phosphate dehydrogenase 
(GPDH) was used to provide a normalization control.  
 
Table 13: List of PCR primers used for RT-PCR 
Gene 
Name 
Accession 
number 
Sequences [5’ -> 3’] size Tm 
[0C] 
PCR 
product 
size 
[bp] 
Human 
AGR2 
NM_006408 Fwd 5’ 217 5’ GCT CCT TGT GGC CCT CTC CTA CAC 3’ 24 60 354 
Rev 3’ 570 5’ ATC CTG GGG ACA TAC TGG CCA TCA 
G 3’ 
25 60 
Human 
GPDH 
NM_002046 Fwd 5’ 628 5’ ACC ACA GTC CAT GCC ATC AC 3’ 20 66 452  
Rev 3’ 1079 5’ TCC ACC ACC CTG TTG CTG TA 3’ 20 67 
Human 
OPN 
NM_0010400
58 
Fwd 5’ 562 5’ GTC ACT GAT TTT CCC ACG GAC CTG 
CC 3’ 
26 76 282 
Rev 3’ 843 5’ TTC ATA ACT GTC CTT CCC ACG GCT 
GT 3’ 
26 73 
Human 
S100A4 
NM_002961 Fwd 5’ 70 5’ ATG GCG TGC CCT CTG GAG AAG G 3’ 22 74 306 
Rev  3’ 375 5’ TCA TTT CTT CCT GGG CTG CTT A 3’ 22 67 
Human 
S100P 
NM_005980 Fwd 5’ 211 5’ GGA GCT ACC AGG CTT CCT GCA GAG 
TGG 3’ 
27 76 180 
Rev 3’ 390 5’ CCA GGG CAT CAT TTG AGT CCT GCC 
3’  
24 75 
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2.5.b.ii.5   AGAROSE GEL ELECTROPHORESIS  
 
PCR products were visualized with SYBR Safe (Invitrogen Ltd., Paisley, United 
Kingdom) or Ethidium Bromide. PCR product identity was confirmed by a correct 
sized band by agarose gel electrophoresis and DNA sequence analysis of the PCR 
product.  
0.5g of agarose powder was added to  50ml of 1xTAE buffer (Tris base, EDTA and 
acetic acid (pH8.0)) and heated in a microwave. The solution was left to cool to about 
60°C. Once cooled, stock of either 5ul ethidium bromide (10mg/ml) or 2ul SYBR 
Safe was added to the agarose mixture. Ethidium bromide and SYBR safe intercalated 
into the double stranded cDNA and allows for visualization under ultraviolet light. 
The mixture was then gently mixed, poured into the gel tray without delay and 
allowed to set for 30 minutes. A gel comb was placed across the top of the gel to 
create wells in order to place the cDNA samples. While the gel was setting, about 
500mL of electrophoresis buffer (1xTAE buffer) was poured into a electrophoresis 
tank, enough to cover the agarose gel by 1-2mm. 1ul of loading buffer and 4ul of the 
PCR product was added to individual sample tubes using fresh pipette tips for each 
sample to prevent cross-contamination. All tubes were vortexed and centrifuged, prior 
to transfer into the wells. For each set of samples for the four MIP’s, a negative and 
positive control was included.  
Once the gel was set, the comb was removed and the gel tray was carefully placed in 
an electrophoresis tank, which was filled with electrophoresis buffer. 5ul of the 
sample was transferred into each well. 1uL of the DNA ladder (molecular weight 
marker) was then placed at the end in one of the wells. It was important to avoid 
! G)!
making any mistakes in recording the order of the samples and to use new clean 
pipette tips for each sample, control or marker to prevent contamination. 
Once all the samples were transferred, the lid was placed on the electrophoretic tank 
and its electrodes were connected to electrophoresis current supply unit and run at 
about 90-100 volts for 30-40 min. The gel was then removed from the electrophoresis 
tank and placed on a UV transilluminator and a photograph of the gel was taken. This 
photograph helped to verify the presence of the PCR products and hence was used for 
the quantification process.  
 
2.5.b.iii   RT-PCR ANALYSIS 
 
PCR bands produced from RT-PCR technique were quantified using ImageJ software 
(Version 1.44o, USA). The pixel intensity of each column was calculated, creating a 
histogram for each the values, with pixel location on the x-axis and intensity value on 
the y-axis (See example in figure 2). The area under the curve represents the amount 
of signal in the band. For all the MIPs, the area of each band (i.e. sample) was 
calculated three times, from which the average was then calculated and used for 
further analysis.  
 
 
 
 
Figure 2: Example of a histogram plot 
generated from quantifying a mRNA sample 
using Image J 
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Normalisation of target gene expression levels must be performed to compensate 
intra- and inter-kinetic RT-PCR variations (sample-to-sample and run-to-run 
variations). All samples were normalised against their corresponding GAPDH PCR 
band, using the calculation: AX x (G1/GY) Where X is variable. See table 14 for 
examples: 
 
AX: Sample to be normalised, e.g. AGR2 Endo Ca A 
G1: GAPDH Endo Ca Sample A (used for all other AGR2 samples in the sample set) 
GX: GAPDH sample being normalized.  
 
     Table 14: Normalisation calculation for quantifying PCR bands 
Samples Calculation 
Sample A Sample A x (GAPDH A/GAPDH A) 
Sample B Sample B x (GAPDH A/GAPDH B 
Sample C Sample C x (GAPDH A/GAPDH C) 
 
Once normalized values were calculated, data was statistically analysed.  
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2.6 STATISTICAL ANALYSIS 
!
 
All data used were analysed using Graph Pad Prism 5 for Mac, GraphPad software 
(version 5.0d, USA). Two normal control groups (Normal Fertile Control and Post 
Menopausal Control) were used to directly compare Endometrial Cancer 
immunohistochemistry results. Non-parametric Mann Whitney test, which does not 
assume Gaussian distribution, was used to compare Endometrial Cancer samples with 
the two control groups independently. We further analysed the Normal Fertile Control 
group compared with the Post Menopausal Control group to ascertain any difference 
between those two independent groups. Pearson’s correlation test, which assumes 
Gaussian distribution was also, used to ascertain an association between Endometrial 
Cancer and FIGO grade.  
Normal Fertile Control samples were compared with Endometrial Cancer samples for 
PCR, along with a positive internal control using endometriosis samples. Non-
parametric Kruskal-Wallis test, which does not assume Gaussian distribution, was 
used to compare PCR results of Endometrial Cancer, Normal Fertile Control and 
Endometriosis (positive internal) Control groups.  
Data with a p value of < 0.05 was deemed as statistically significant and p value of 
<0.1 as a trend between <0.1 and <0.05. 
!
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3 RT-PCR OPTIMIZATION !!
 
Reverse transcriptase polymerase chain reaction is the most sensitive technique for 
mRNA detection and quantification. In this study it was used as an alternative 
confirmatory test to our IHC study of endometrial MIPs. 
RNA was extracted from a total of 22 endometrial samples for the analysis of 
Osteopontin, S100P, S100A4 and AGR2 expression by RT-PCR. Two control groups 
were included for the comparison with endometrial cancer samples, normal fertile and 
as a positive internal control, endometriosis samples. We were not able to extract 
RNA from postmenopausal endometrial pipelle biopsies due to insufficient quality or 
quantity. 
From the RNA samples extracted, successful results for all the MIPs were obtained 
and analysed from eight sample; two endometrial cancers, three normal fertile and 
three endometriosis samples. This was again due to either the insufficient quality or 
quantity of RNA in the samples collected. 
 
3.1 RNA QUALITY TEST 
 
 
To test which RNA extraction method would the most successful, an endometrial 
cancer sample (A) with stored frozen and paraffin embedded samples was chosen. 
This sample was also cultured for several months, successfully creating a primary cell 
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line. The RNA extracted from the cultured cells, if successfully amplified, would be 
used as an internal control. RNA was therefore extracted from the cultured cells, 
frozen and sections of the paraffin embedded sample, using the two different methods 
explained in the previous chapter.  
RNA concentrations from all three variants of the endometrial cancer sample (A) 
were calculated. The optical density ratio was calculated: 
Cultured Cells = 1.931 
Frozen = 2.01 
Paraffin = 0.893 
 
An optical density ratio of  >1.8 is considered satisfactory; therefore we eliminated 
the RNA extracted from the paraffin sample for this PCR run.  
AGR-2 primer was used to test the two samples, including GAPDH to provide a 
normalization control. 1st c-DNA reaction mixture was made for each sample and 
amplified by PCR on 29 cycle programme. Agarose gel electrophoresis results are 
show below in Figure 3: 
 
 
 
 
 
! GAPDH (452bp) 
        M!! !!!!!! !!!!!!!!1             2           3              4     !
Figure 3: GAPDH and AGR2 testing culture cells and frozen section of an endometrial cancer sample A. 
Lane M: DNA ladder, Lane 1: AGR2 Culture Cells, Lane 2: Frozen, Lane 3: GAPDH Cultured Cells, 4: 
GAPDH Frozen 
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Results show that both frozen and culture cell samples were negative for AGR2. 
However a positive control was not included in this run, so the result seen could not 
be verified.  
A PCR was run testing the culture cells, frozen and paraffin endometrial cancer 
samples, including a positive control for AGR2 (MCF7 breast cell line). As the 
optical density ratio was only 0.893 for the paraffin, various conditions were 
examined. Two different 1st c-DNA reaction mixtures were made for AGR2 and 
GAPDH, one with 2ug of total RNA and other with 4ug. Both c-DNA mixtures were 
then amplified at 30 cycles and 40 cycles. Hence testing 2µg at 30 cycles, 2µg at 40 
cycles and 4µg at 30 cycles, 4µg at 40 cycles. See Figure 4 for the gel picture: 
       GAPDH       AGR2 
 
 
 
 
 
The frozen tissue and culture cells were still negative for AGR2, in comparison to the 
MCF7 positive control. 4µg of total paraffin RNA at 40 cycles amplified enough 
RNA for a band to be visible. GAPDH band for 4µg paraffin at 40 cycles has also 
been amplified the most compared to the other conditions set for the paraffin sections. 
 1      2     3     4     5     6     7           M         9    10    11    12   13   14   15 !
Figure 4: GAPDH PCR for testing different RNA extraction methods on endometrial cancer sample (A). 1-
7: GAPDH, 9-15: AGR2. 1 & 9: Paraffin 2µg 30 cycles, 2 & 10: Paraffin 2µg 40 cycles, 3 & 11: Paraffin 4µg 
30 cycles, 4 & 12: Paraffin 4µg 40 cycles, 5 & 13: Frozen tissue, 6 & 14: Culture cells, 7 & 15: MCF7 
positive control. 
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Results therefore suggest that RNA extraction from paraffin sections is a suitable 
method, which can be used for the PCR amplification of other samples.  
Following this RNA was extracted from sections of a further 10 paraffin embedded 
endometrial tissue sample (B-K), three normal fertile, four endometriosis and three 
endometrial cancer samples.  GAPDH and AGR2 primers were tested on these sample, 
see gel pictures Fig 5 and 6 below: 
 
 
 
 
 
 
 
 
 
 
 
There is a high level of primer dimer amplified below the RNA sample, which can be 
due to various reasons including the use of non-purified RNA samples, reduced cycle 
length etc.  
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! AGR2 (354bp) 
Figure 5: GAPDH PCR for samples B-K. Lane M: DNA Ladder, 1-3: Normal fertile, 4-7: 
Endometriosis, 8-10: Endo Cancer, 11: Positive control 
 
Figure 6: AGR2 for samples B-K. Lane M: DNA ladder, Lanes 1-3: Normal fertile control, Lanes 4-7: 
Endometriosis and Lanes 8-10: Endometrial cancer.  
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A clear difference was seen between the three different groups for the expression of 
AGR2, so the 11 samples (A-K) were analysed for the expression of S100A4, S100P 
and OPN.  
Results showed varied positive and negative expression for S100P in the RNA A-K 
samples, however the RNA of the samples were not amplified for the expression of 
S100A4 or OPN. See Fig 7-9: 
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Figure 7: S100A4 expression for sample A-K, 1: Positive control, 2: Negative control, 3-5: Normal fertile 
control, Lanes 6-9: Endometriosis and Lanes 10-12: Endometrial cancer, Lane M: DNA ladder. 
Figure 8: S100P expression for samples A-K. Lane 1-3: Normal fertile, 4-7: Endometriosis, 8-11: 
Endometrial cancer, M: DNA ladder. 
Figure 9: S100A4 expression for sample A-K. Lane M: DNA ladder, 1: Negative control, 2: Positive control, 
3-5: Normal fertile control, Lanes 6-9: Endometriosis and Lanes 10-13: Endometrial cancer.  
 
! **!
The paraffin sections used for the samples may have not extracted enough RNA for 
S100A4 or OPN to amplify, therefore different samples were chosen to analyse. RNA 
was extracted from the frozen or RNA later sections for the new set of samples. This 
method was chosen, as it is known to produce a more purified concentration of total 
RNA. 
 
3.2  PCR CONDITION TESTING !
 
RNA was extracted from a new set of 11 endometrial samples, three normal fertile, 
five endometriosis and three endometrial cancers. RNA concentration was calculated 
for each sample, but three samples (one endometriosis and two endometrial cancers) 
were far too dilute to be used and removed from the new set.  
The RNAs (L-V) were amplified with a 40cycle programme examining the expression 
of AGR2 and GAPDH as a normalization control. Gel electrophoresis observed an 
over amplification of the RNA for both AGR2 and GAPDH. See Fig 10 and 11. This 
initiated a re-evaluation of the conditions used for the PCR amplification of these 
samples, as the RNA is more purified compared to the paraffin sections.  
 
 
 
 
 
 
  M       1    2       3      4       5       6       7       8      9      10     11!
! GAPDH (452bp) 
Figure 10: GAPDH expression for samples L-V. Lane M: DNA Marker, 1: Positive control, 2: 
Negative control, 3-5: Normal fertile, 6-9: Endometriosis, 10-11: Endometrial cancer. 
! *>!
 
 
 
 
 
.  
 
The cycle length was reduced to 30 cycles to assess whether it altered the 
amplification. One normal fertile (L), one endometriosis (O) and two endometrial 
cancer samples (U&V) were tested for S100A4 and OPN at 30 and 40 cycles. Results 
showed that the cycle length need to be further reduced. See Fig 12: 
   S100A4             OPN 
 
 
 
A further PCR run was done assessing the sample at cycles 20, 22, 24 and 28 using 
the endometriosis sample (O) and endometrial cancer sample (U). This revealed that 
the optimum cycle length for S100A4 and OPN would be 26 cycles. See Fig 13: 
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! AGR2 (354bp) 
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Figure 11: AGR2 expression for samples L-V. Lane M: DNA Marker, 1: Positive control, 2: 
Negative control, 3-5: Normal fertile, 6-9: Endometriosis, 10-11: Endometrial cancer.  
 
Figure 12: Testing S100A4 and OPN on New RNA samples (L, O, U & V) at 30cycles and 40cycles. Lane M: 
DNA marker, 1-8: S100A4, 9-16: OPN. 1: Normal (L) 30C, 2: Normal (L) 40C, 3:Endometriosis (O) 30C, 4: 
Endometriosis (O) 40C, 5: Endometrial cancer (U) 30C, 6: Endometrial cancer (U) 40C.  7: Endometrial 
cancer (V) 30C, 8: Endometrial cancer (V) 40C. Repeat for 9-16 OPN. 
! *)!
   
 
 
 
 
 
Figure 13: Testing S100A4 on new RNA sample (O & U). Lane M: DNA Ladder, 1: Negative control, 2: 
Positive control, 3-6: Endometriosis sample (0) 3: 20 cycle, 4: 22 cycle, 5: 24 cycle, 6: 28 cycle. Repeat for 7-
10 for Endometrial cancer sample U. 
 
 
Once the optimal conditions were established for the four MIPs for the new set of 
RNA. RT-PCR was run to assess the expression of the four MIPs in normal and 
endometrial cancer. The next chapter (Results) will discuss and analyse the results 
further. 
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4 RESULTS !
 
This study was completed in approximately twelve months period from September 
2010 to August 2011 and used a total of 55 endometrial samples, 30 from women 
with endometrial cancer, 15 from normal fertile women with regular menstrual cycles 
and 10 from post-menopausal women. Functionalis layer of the endometrium was 
collected with pipelle endometrial sampler hence only the functional layer of the 
endometrium is analysed for the purpose of this study.  
 
4.1 PATIENT DEMOGRAPHICS !
 
Over 80 endometrial samples were collected from normal fertile women over the last 
12 months. All samples were histologically dated according to modified Noyes 
criteria (Murray et al 2004), also taking in to consideration of the last menstrual 
period according to the woman’s recollection and her declared regularity of the cycle. 
We included two normal control groups to directly compare with the endometrial 
cancer samples. Since most women develop endometrial cancer in the 
postmenopausal period, postmenopausal endometrial samples were collected and used 
a control group. In the normal fertile women, we chose to study only endometrial 
samples that were assigned to the proliferative phase of the cycle as another control 
group. Previous literature reports both these endometrial sample groups being used to 
compare with endometrial cancer samples as control groups, hence our choice to 
include both groups.  
! *E!
4.1.a DEMOGRAPHIC DETAILS 
 
Fertile women included in the study had no history of endometriosis or pathological 
abnormality of the endometrium. They were undergoing laparoscopic sterilization or 
unrelated operation, and were not on any hormonal treatments. Likewise for the post-
menopausal women recruited, participants had no history of abnormal bleeding or 
endometrial pathology. They were not on any hormonal replacement therapy and 
underwent hysterectomies for prolapse.  
As expected the pre-menopausal women were younger than the other two groups 
(KW test, p < 0.0001, see Table 15). BMI was higher in patients with endometrial 
cancer compared the two control groups, but not statistically different. (KW test, p = 
0.0971). In three patients I was unable to find the demographic information to include 
in this analysis. 
Table 15: Mean age and BMI of individuals in each study group 
Study Groups Mean Age 
(±SD) 
Mean BMI 
(±SD) 
Normal Fertile 40.20 ± 4.97 28.44 ± 5.99 
Post Menopause 66.70 ± 7.48 28.24 ± 3.93 
Endometrial Cancer 66.82 ± 9.46 32.23 ± 7.50 
 
 
 !!
 !
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4.1.b  ENDOMETRIAL CANCER TYPES 
 
As expected 81.5% of women in our study had endometrioid adenocarcinoma, 11% 
with endometrial carcinosarcoma and 7.4% with mixed variants (mixed serous and 
endometrioid adenocarcinoma). I was unable to retrieve the detailed pathology report 
describing the cancer type for 3 patients. (See Table 16) 
Table 16: Grouping cancer type 
Cancer Type Sample Numbers Percentage (%) 
Endometrioid endometrial adenocarcinoma 22 81.5 
Carcinosarcoma 3 11 
Other 2 7.4 
Detailed pathology report unavailable 3 11 
 
Histological grading only applies to endometrioid endometrial adenocarcinomas, 
other non-endometrioid carcinomas including serous and clear-cell are automatically 
classed as grade 3. International Federation of Gynecology and Obstetrics (FIGO) 
grading scheme was used to grade the endometrioid endometrial adenocarcinomas as 
described in chapter one. 50% of the endometrioid endometrial cancer sample set was 
FIGO grade 1 endometrioid endometrial adenocarcinoma (See table 17) 
       Table 17: Grouping FIGO grade for endometrioid endometrial adenocarcinoma 
FIGO Grade Sample Number Percentage (%) 
1 11 50 
2 8 36.4 
3 3 13.6 
! >(!
All diagnosed cancers are staged using the FIGO staging scheme as described in 
chapter one. FIGO stage data was retrieved from the pathology reports for 25 of the 
endometrial cancers in my study group.  52% of women with endometrial cancer were 
diagnosed at an early stage (IA) and subsequently treated with a hysterectomy (See 
table 18). 
 
Table 18: FIGO Stage of all cancers 
FIGO Stage Sample Number Percentage (%) 
IA 13 52 
IB 6 24 
II 4 16 
IIIA 0 0 
Stage IIIB 2 8 
Stage IIIC1 0 0 
Stage IIIC2 0 0 
Stage IVA 0 0 
Stage IVB 0 0 !!!!!!!
! >'!
4.2 IMMUNOHISTOCHEMISTRY 
 
Staining intensity of the MIPs in endometrial cancer cells were compared to the 
following three difference cellular compartments of the normal fertile control 
samples; Glandular epithelium, luminal epithelium and stroma (See Figure 14 below). 
We also made observations as to if there were differential staining in the nuclear and 
cytoplasmic compartments of the endometrial cells for the four MIPs and if there was 
differential blood vessel associated staining.  
The endometrial samples obtained from healthy, normal postmenopausal women 
contained very thin, sparse amount of intact endometrium. Therefore the Quick Score 
method of analysis (which require analyzing 10 high power fields) was not 
appropriate or feasible. Postmenopausal samples were consequently analyzed using 
intensity scoring with descriptive localisation remarks for all three compartments, 
glandular epithelium, luminal epithelium and stroma.  
 
 
 
 
 
 
Figure 14: Demonstrating the different cellular compartments in a normal fertile control sample (A) and 
endometrial cancer cells in a endometrial cancer sample (B). (40x magnification) 
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4.2.a  OSTEOPONTIN 
 
In the normal fertile control OPN was primarily localised in the epithelium and in the 
blood vessels. In the epithelial compartment cytoplasmic staining was observed in 
both glandular and luminal epithelial cells. Moderate staining was seen in the vessels 
as seen in Fig 15. 
 
 
 
 
 
 
 
 
 
 
 
 
OPN immuno-staining was primarily localised in the cytoplasm of glandular 
epithelial cells in the postmenopausal endometrium (See Fig 16). There is distinct and 
statistically significant difference observed between the OPN expression in normal 
fertile and postmenopausal glandular epithelial cells (Mann Whitney U test p < 
0.0001).   
Figure 15: OPN IHC: Demonstrating moderate immuno-staining in the different 
cellular compartments. A: Glandular epithelium, B: Luminal epithelium, C: 
Vessels, D: Positive/Negative control. {40xmagnification}!
! >G!
  
 
 
Both cytoplasmic and nuclear staining was seen in the endometrial cancer cells as 
seen in Figures 17 and 18. Results comparing staining intensity of endometrial cancer 
cells and intensity in stromal compartment of normal fertile controls would be skewed 
since OPN is not normally present in the stroma. Therefore comparison between 
glandular and luminal epithelial cellular compartments with endometrial cancer cells 
will only be discussed. 
 
Figure 16: Comparison between OPN immuno-staining seen in glandular epithelium of normal fertile (FC) and 
postmenopausal (PM) endometrium. {40xmagnification} Results are represented as mean ± SD, FC n=15, PM n=10!
! >*!
 
 
  
Compared to the proliferative phase normal control endometrium, endometrial cancer 
cells showed decreased OPN immuno-staining seen in Figure 17. This difference was 
significant between the expression of OPN in endometrial cancer cells and glandular 
(Mann Whitney U test; p=0.0047) and luminal epithelial cells (Mann Whitney U test; 
p=0.0018). Therefore, endometrial cancer cells loose the expression of OPN 
compared to normal epithelial cells in the proliferative phase. 
 
OPN Endo Ca Vs N. Fertile
En
do
 C
an
ce
r O
PN
FC
 O
PN
 G
lan
ds
FC
 O
PN
 LE
FC
 O
PN
 St
ro
ma
`
0
5
10
15
Study Groups
Q
ui
ck
 S
co
re
Figure 17: Comparison between OPN immuno-staining seen in endometrial cancer cells (CA) and normal 
fertile control (FC) {40xmagnifiaction} Results are represented as mean ± SD, FC n=15, CA n=30!
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When comparing immuno-staining between postmenopausal endometrium and 
endometrial cancer cell, results suggest endometrial cancer cells to have higher 
immuno-reactivity to OPN than postmenopausal endometrium. See Fig 18. 
There was a statistically significant difference seen between the immuno-staining of 
OPN in endometrial cancer cells and all cellular compartments in postmenopausal 
endometrium.  
 
 
 
 
Figure 18: Comparison between OPN immuno-staining seen in endometrial cancer cells (CA) and 
postmenopausal endometrium (PM). {40xmagnification} Results are represented as mean ± SD, PM n=10, 
CA n=30.!
! !!!!"#$%$$$(!!!!!!!!"*$%$$$(!!!!!!!!"*$%$$$(!
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No correlation was observed between osteopontin immuno-staining and FIGO grade 
of all the endometrioid endometrial cancers in the sample set of the study (Pearson’s 
correlation r = 0.3027, p = 0.1709) as seen in Fig 19. 
 
 
Figure 19: Correlation graph showing the relationship between OPN and FIGO Grade of endometrioid 
endometrial cancer !
 
 
 
 
 
 
 !!!
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4.2.b S100P 
 
Endometrial immuno-reactivity for S100P was largely confined to the stromal 
compartment in the proliferative phase control group, but occasionally a few positive 
cells were seen in the glandular and luminal epithelium. Both nuclear and cytoplasmic 
staining was observed. Blood vessels were also moderately stained in a few of the 
sample where the staining was seen in the below, Fig 20.  
 
 
 
 
 
 
 
 
 
Weak-moderate staining was seen in the glandular epithelial compartment in 
postmenopausal endometrium, localised to the cytoplasm of the cells (Fig 21). There 
was a statistically significant difference observed between glandular epithelial 
immuno-stain between the two control groups (Mann Whitney U test; p=0.0207).  
Figure 20: IHC for S100P; A: Stromal stain, B: Glandular and luminal 
epithelial, C: Vascular, D: Positive and negative control. {40xmagnification)!
! >E!
 
 
Both cytoplasmic and nuclear staining was observed in the endometrial cancer cells 
(Fig 22 and 23). Our results show apparently increased immuno-staining for S100P in 
endometrial cancer cells when compared to all cellular compartments in normal fertile 
control (Fig 23). However, this differential staining of the endometrial cancer cells 
was statistical significant only when compared with the stromal compartment (Mann 
Whitney U test; p < 0.0221). 
 
Figure 21: Comparison of IHC on normal fertile (FC) and postmenopausal (PM) glandular epithelium. 
{40xmagnification} Results are represented as mean ± SD, FC n=15, PM n=10!
! )%!
 
 
S100P immuno-reactivity was not observed in the normal postmenopausal 
endometrium compared to endometrial cancer cells (Fig 23). The difference observed 
between the two groups was statistically significant, with an increased immuno-
reactivity to S100P seen in endometrial cancer cells. 
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Figure 22: IHC Comparison between of S100P normal fertile (FC) and endometrial cancer (CA). {40xmagnification} 
Results are represented as mean ± SD, FC n=15, CA n=30!
! !!!!!!!!!!"#$%+,''!!!!!!!!"#$%',&+!!!!!!!!"#$%$++(!
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There was no association seen between S100P expression and the different FIGO 
grades of endometrioid endometrial cancers (Pearson’s correlation, r = 0.3700, p = 
0.0901). As shown below in Fig 24: 
 
Figure 24: Graph showing the correlation between S100P and FIGO grade of endometrioid endometrial 
cancer 
Figure 23: IHC comparison between endometrial cancer cells (CA) and postmenopausal endometrium (PM). 
{40xmagnification) Results are represented as mean ± SD, PM n=10, CA n=30!
! !!!!!!"#$%$$$+!!!!!!!!"*$%$$$(!!!!!!!!"*$%$$$(!
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4.2.c AGR-2 
 
Normal fertile control samples showed immuno-staining for AGR2 in the glandular 
and luminal epithelium, where the immuno-staining was seen in the epithelial cell 
cytoplasm. No vascular staining was observed in the normal fertile control samples 
(Fig 25).  
 
 
 
 
 
Normal postmenopausal samples showed immuno-staining for AGR2 expression in 
the cytoplasm of glandular and luminal epithelial compartments (Fig 26). In 
comparison to the normal fertile endometrium, a significant difference was seen in the 
expression of AGR2, with reduced immuno-stain observed in the postmenopausal 
samples (Mann Whitney U test; Glandular epithelium p < 0.0001, Luminal epithelium 
p < 0.0003).  
 
Figure 25: IHC showing AGR2 immuno-stain in different cellular compartments. A: Luminal epithelium, B: Glandular 
epithelium, C: Positive/negative control. {40xmagnifiaction}!
! )F!
 
 
Positively stained endometrial cancer cells showed immune-reactivity for AGR2 both 
in the nucleus and in the cytoplasm (Figure 27 and 28). Results comparing staining 
intensity of endometrial cancer cells and intensity in stromal compartment of normal 
fertile controls would be skewed since AGR2 is not normally present in the stroma. 
Therefore comparison between glandular and luminal epithelial cellular 
compartments with endometrial cancer cells will only be discussed. 
Figure 26: Comparison between normal fertile (FC) and postmenopausal (PM) AGR2 immuno-stain. 
{40xmagnification} Results are represented as mean ± SD, FC n=15, PM n=10!
! )G!
 
    
Results generated suggest that endometrial cancer cells express less AGR2 compared 
to normal fertile epithelial cells (Fig 27). However, semi-quantitative comparison of 
immuno-staining for AGR2 between all endometrial cancer cells and the fertile 
controls do not show a statistically significant difference (Mann Whitney U test; 
Glandular epithelium p < 0.1736, Luminal epithelium p < 0.1175). 
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Figure 27: Comparison between AGR2 immuno-stain on endometrial cancer cells (CA) and normal fertile (FC) 
endometrium. {40xmagnification} Results are represented as mean ± SD, FC n=15, CA n=30!
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However, in comparison to postmenopausal endometrium, endometrial cancer cells 
have been shown to over express AGR2 (Fig 28).  
 
 
The results showed a significant difference between the two groups, demonstrating an 
increased immuno-reactivity to AGR2 in endometrial cancer cells. 
 
  
 
 
 
 
Figure 28: IHC comparing immuno-staining of AGR2 between endometrial cancer cell and postmenopausal 
endometrium. {40xmagnifiaction} Results are represented as mean ± SD, PM n=10, CA n=30.!
! !"*$%$$$(!!!!!!!!"*$%$$$(!!!!!!!!"*$%$$$(!
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No correlation was observed between immuno-staining of AGR2 in endometrial 
cancer cells and their FIGO grading (Pearson correlation r = -0.3689, p = 0.0911). See 
Figure 29 below: 
 
 
Figure 29: Graph showing the correlation between AGR2 and FIGO grade of endometrioid endometrial 
cancer !!
 
 
 
 
 
 
 
 !
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4.2.d S100A4 
 
Positive immuno-staining was observed predominantly in the stromal compartment of 
normal fertile control samples, localised to both to the cytoplasm and nucleus. There 
were occasional (<1 in 50 cells) nuclear and cytoplasmic epithelial cell S100A4 
staining seen. Moderate S100A4 immuno-staining was also localized to blood vessels 
of normal fertile control endometrium (Fig 30). 
 
 
 
 
 
 
 
Moderate staining of S100A4 was seen in all cellular compartments in the normal 
postmenopausal endometrium. Immuno-staining was localised to the nucleus and 
cytoplasm of epithelial and stromal cells (Fig 31). A statistically significant difference 
was only generated between the normal fertile and postmenopausal endometrium in 
the stromal and glandular epithelial cellular compartments (Mann Whitney U test; 
Stromal p = 0.0034, Glandular epithelium p < 0.0001). Stromal S100A4 immuno-
reactivity was higher in normal fertile endometrium, and glandular staining was lower 
in comparison to postmenopausal endometrium. 
 
Figure 30: S100A4 staining observed in epithelial, stromal and vascular compartments. A: Stromal, 
B: Epithelial, C: Vessels, D: Positive/negative control. {40xmagnification} 
 
! )N!
 
 
Cytoplasmic S100A4 staining was observed in positive endometrial cancer cells (Fig 
32 and 33). In comparison to normal fertile endometrium, a statistical difference was 
seen, demonstrating the over expression of S100A4 in endometrial cancer cells (Fig 
32). All three normal fertile endometrial cell compartments studied showed a 
statistically significant difference compared with endometrial cancer cells. 
 
Figure 31: Comparison between normal fertile (NF) and postmenopausal (PM) endometrium for S100A4 
staining. {40xmagnification} Results are represented as mean ± SD, FC n=15, PM n=10!
! )E!
 
 
The results also showed increased immuno-reactivity for S100A4 in endometrial 
cancer cells in comparison to normal postmenopausal endometrium (Fig 33). The 
difference observed between the three cellular compartments was statistically 
significant. 
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Figure 32: Comparing immuno-stain of S100A4 between endometrial cancer cells (CA) and normal fertile (FC) 
endometrium. {40xmagnification} Results are represented as mean ± SD, FC n=15, CA n=30!
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There was no correlation seen between endometrial cancer grade and expression of 
S100A4 (Pearson correlation r = -0.3339, p = 0.1288). See Fig 34 below: 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Correlation graph showing the relationship between S100A4 immuno-stain and FIGO Grade 
Figure 33: IHC results comparing S100A4 staining between endometrial cancer cells (CA) and postmenopausal 
endometrium (PM) {40xmagnification} Results are represented as mean ± SD, PM n=10, CA n=30!
! !!!"#$%$$$/!!!!!!!!"*$%$$$(!!!!!!!!"#$%$$$&!
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4.3  RT-PCR 
 
The occurrence of the MIPs mRNA in human benign endometrial tissue and 
malignant endometrial carcinomas were examined by revere transcription- PCR. Band 
intensities for each sample were obtained using Image J software and normalized with 
its corresponding GAPDH band (Fig 35, Tables 19 & 20). 
Mann Whitney U test could not be carried out for the direct comparison of normal 
fertile and endometrial cancer sample, as a minimum of three samples in each group 
is required. Therefore Kruskal-Wallis statistical test was perfomed comparing all 
three groups (normal fertile control, endometriosis and endometrial cancer). 
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Figure 35: GAPDH normalization control for samples (L-V) Lane M: DNA Ladder, Lane 1: Negative 
control, 2: Positive control, 3-5: Normal fertile, 6-8: Endometriosis, 9 &10: Endometrial Cancer.!
! GAPDH (452bp) 
! N'!
     Table 19: Average and normalized values for OPN and S100P mRNA samples 
Samples OPN S100P 
Average Normalized Average Normalized 
Endometriosis 11928 11928 7628 7628 
Endometriosis 17336 10507 7741 4692 
Endometriosis 17194 10473 15721 9576 
Normal 6643 4939 671 499 
Normal 3575 2328 282 184 
Normal 4192 2656 639 405 
Endo Ca 16855 10385 12192 7512 
Endo Ca 14863 15503 1183 1234 
          
 
Results suggest that endometrial cancer cells over express Osteopontin (KW test; p = 
0.0821), S100P (KW test; p = 0.0622) and S100A4 (KW test;  p = 0.0622) mRNA in 
comparison to normal fertile endometrium. However, no statistically significance was 
observed. (See figures 36 and 37 for OPN, 38 and 39 for S100P & 42 and 43 for 
S100A4 results). 
 
 
! NF!
      Table 20: Average and normalized values for AGR2 and S100A4 mRNA samples 
Samples AGR2 S100A4 
Average Normalized Average Normalized 
Endometriosis 6030 6030 4774 4774 
Endometriosis 7879 4775 7962 4826 
Endometriosis 10036 6113 10183 6202 
Normal 9190 6833 4286 3187 
Normal 4392 2860 3714 2418 
Normal 4573 2897 3314 2099 
Endo Ca 2203 1357 5301 3266 
Endo Ca 4330 4517 2853 2975 
  
 
Likewise, no significant difference was observed for AGR2 mRNA expression 
between the endometrial cancer and normal fertile control samples (KW test; p = 
0.2905). Results suggest there to be an apparent reduction of AGR2 expression in 
endometrial cancer cells.  See figures 40 & 41. 
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4.3.a  OSTEOPONTIN 
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Figure 37: Box plot comparing OPN mRNA expression between Endo cancer, normal fertile and 
endometriosis samples. Results are represented as mean ± SD. 
Figure 36: OPNmRNA expression for samples (L-V) Lane M: DNA Ladder, Lane 1: Negative control, 2: 
Positive control, 3-5: Normal fertile, 6-8: Endometriosis, 9 &10: Endometrial Cancer.!
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4.3.b  S100P 
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Figure 39: Box plot comparing S100P mRNA expression between Endo cancer, normal fertile and 
endometriosis samples. Results are represented as mean ± SD. 
Figure 38: S100PmRNA expression for samples (L-V) Lane M: DNA Ladder, Lane 1: Negative control, 2: 
Positive control, 3-5: Normal fertile, 6-8: Endometriosis, 9 &10: Endometrial Cancer. 
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4.3.c  AGR2 
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Figure 41: Box plot comparing AGR2 mRNA expression between Endo cancer, normal fertile and 
endometriosis samples. Results are represented as mean ± SD. 
 
Figure 40: AGR2mRNA expression for samples (L-V) Lane M: DNA Ladder, Lane 1: Negative control, 2: 
Positive control, 3-5: Normal fertile, 6-8: Endometriosis, 9 &10: Endometrial Cancer.!
!!!!"#$%+/$,!!!
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4.3.d  S100A4 
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Figure 43: Box plot comparing OPN mRNA expression between Endo cancer, normal fertile and 
endometriosis samples. Results are represented as mean ± SD. 
 
Overall results from RT-PCR have confirmed IHC results for the expression of S100P, 
AGR2 and S100A4, however OPN results were contradictory.
Figure 42: S100A4mRNA expression for samples (L-V) Lane M: DNA Ladder, Lane 1: Negative control, 2: 
Positive control, 3-5: Normal fertile, 6-8: Endometriosis, 9 &10: Endometrial Cancer. 
!
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5 DISCUSSION 
 
The aim of this pilot study was to examine the expression of Osteopontin, S100P, 
AGR2 and S100A4 in human endometrial cancer cells. We also included normal 
fertile and postmenopausal endometrium as control groups to detect any aberrant 
expression of the MIPs specific to the endometrial cancer samples. All four metastasis 
inducing proteins were located in the endometria from normal fertile and 
postmenopausal women using immunohistochemistry. Results showed increased 
immuno-reactivity for S100P and S100A4 in endometrial cancer cells, but reduced 
immuno-reactivity was observed for OPN and AGR2. Similar results were also 
generated using reverse transcriptase polymerase chain reaction, for S100P, S100A4 
and AGR2 confirming the immunohistochemistry analysis. However RT-PCR results 
showed that endometrial cancer cells expressed higher levels of OPN compared to 
normal fertile control samples, which is in contrast to our IHC results. These results 
will be discussed in detail in the following chapter. 
 
5.1  NORMAL FERTILE ENDOMETRIUM 
 
 
Endometrial staining results observed in normal fertile proliferative phase 
endometrium for all four MIPs were consistent with previous studies (Hapangama et 
al., 2011 (In press)).  
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5.1.a OSTEOPONTIN 
 
Osteopontin is expressed by epithelial cells in primate and human endometrium 
(Allan et al 2003;Lessey 2002; Odagiri et al 2007). Studies have shown that OPN is a 
progesterone regulated endometrial secretory protein (Johnson et al 2003). OPN has 
been shown to be detectable in both the proliferative and early secretory phase 
endometrium in the glandular and luminal epithelium (Apparao et al 2001). 
Moderate immune-reactivity for OPN was seen in the proliferative phase normal 
fertile endometrial sample in this study, disagreeing with some previous studies but 
agreeing with others (Apparao et al 2001). Staining was localized to cytoplasm of the 
glandular and luminal epithelial cellular compartments. The difference observed 
could be due discrepancies in OPN antibodies and IHC methods used. In previous 
work done in our laboratory, a different OPN antibody (mouse monoclonal anti-
human OPN,) gave a much lower intensity of immuno-staining compared to the rabbit 
polyclonal anti-human OPN I used for my study. Study done by Apparao et al (2001) 
used monoclonal mouse anti-human OPN antibody without conducting antigen 
retrieval step and we carried out high temperature antigen retrieval, which is thought 
to enhance the immuno-staining. 
  
5.1.b S100P 
 
S100P function in the normal endometrium is yet to be determined, but studies have 
suggested that it may play a role in the implantation window (Tong et al 2010; 
Hapangama DK et al., 2011 (In press)).  The protein is primarily localised in both 
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epithelial and stromal compartments in normal fertile endometrium, with weak 
staining in proliferative phase endometrium (Hapangama DK et al., 2011 (In press)). 
S100P mRNA levels were also shown to be at highest in the mid-late secretory phase, 
when systemic levels of progesterone are highest, suggesting S100P is a novel 
progesterone-regulated gene in the endometrium (Xie et al 2006). However, the 
progesterone regulation of S100P is uncertain. In contrast, in breast cancer specimens 
there was no correlation seen between S100P and oestrogen or progesterone receptor 
expression (Wang et al 2006). Further work is required to establish a link between 
progesterone and S100P.  
S100P immuno-reactivity was localised to the stromal cellular compartment in the 
normal fertile endometrium in this study. There was a reduced immune-reactivity 
seen in the normal fertile endometrium compared to immuno-staining observed in 
endometrial cancer cells. S100P is known to have a proliferative role in cancers; 
therefore if there is a similar function in the endometrium, during the proliferative 
phase you would expect to find S100P expression. However, further functional 
studies in vitro need to be undertaken to ascertain this.  
 
5.1.c AGR2 
 
Human AGR2 is known to be strongly expressed in tissues containing mucus 
secreting cells and/or functioning as endocrine organs, this includes glandular 
epithelium in the endometrium (Brychtova et al 2011).   
The first study reporting the expression of AGR2 in human endometrium arises from 
our laboratory (Hapangama et al 2011 (In press)). A cyclical variation in the 
expression of AGR2 in the normal fertile control samples was observed, with weakest 
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immuno-staining seen in the proliferative phase in all cellular compartments except 
endothelial cells. Increased immuno-reactivity of AGR2 was seen in endometriosis 
samples in the secretory phase.  Analysis of AGR2 in my study showed positive 
expression in the glandular and luminal epithelium of normal fertile endometrium 
during the proliferative phase. 
AGR2 is an oestrogen and androgen responsive protein, up regulated in a number of 
cancers, including breast, lung, ovarian, gastric, pancreatic, oesophageal, and prostate. 
Its expression in all premalignant and malignant oesophageal adenocarcinoma 
suggests that it serves an important role in disease pathogenesis (Wang et al 2008). 
Further work is required to elicit the role it plays in the normal endometrium, which 
can be done by undertaking functional studies in vitro. 
 
5.1.d S100A4 
 
S100A4 is localised in the nucleus, cytoplasm, and the extracellular space. 
Cytoplasmic expression is evident in the vast majority of S100A4-expressing cells 
(Boye & Maelandsmo 2010). A study investigating expression of the MIPs in normal 
endometrium showed that S100A4 was immuno-localised to the endometrial stromal, 
perivascular and endothelial cells of normal fertile women (Hapangama et al 2011 (In 
press)). 
Similar results were obtained from this study, where immuno-stain was primarily 
localised to the stromal compartment of the normal fertile control endometrium. 
S100P and S100A4 belong to the S100 family of calcium-binding proteins, which 
have been shown to play a fundamental role in the metastatic phase of cancer (Wang 
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et al 2006; Grigorian et al 2008). Recent work has been reviewed, demonstrating 
S100A4-mediated effects on cell proliferation, apoptosis and tumor growth (Sherbet 
2009). This may suggest that S100A4 has a proliferative function in normal 
endometrial cells, hence expressed in the proliferative phase. 
 
5.2  POST MENOPAUSAL ENDOMETRIUM 
 
 
Endometrial cancer is most commonly diagnosed in women after their menopause, so 
as well as using normal fertile samples, the use of post-menopausal endometrial 
samples as a control is the most useful.   
The role and function of the four MIPs in pre-menopausal endometrium is still largely 
unknown. The functional involvement of the MIPs that may occur in the normal 
fertile endometrium may not be relevant in the endometria of post-menopausal 
women for obvious reasons. However, postmenopausal endometrium although not 
cycling due to lack of ovarian hormone cyclicity, still retains the ability to respond to 
ovarian hormones if available. Therefore although normally not functional, the 
functional potential is retained.  
The immuno-staining of the MIPs on both the control groups, normal fertile women 
during the proliferative phase and postmenopausal endometrium, were analysed and 
compared to ascertain the most suitable control group to understand the functional 
relevance and also the diagnostic, clinical relevance of MIPs in endometrial cancers.  
If the MIPs were absent in postmenopausal endometrium it could be significant 
marker of pre-malignant or malignant change. However, to confirm this hypothesis 
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larger number of normal postmenopausal endometrial samples; endometrial 
hyperplasia samples and early stage endometrial cancers will need to be studied in the 
future. One difficulty that can be foreseen is the expression of the MIPs in pre-
menopausal endometrium.  
One would envisage similar expression in the women on hormone replacement 
therapy and therefore MIPs may not be able to distinguish malignant changes if the 
women have been exposed to HRT. Since some HRT preparations increase the risk of 
development of endometrial cancer this may be an important question that need to be 
addressed in future studies 
All postmenopausal samples showed a decreased immuno-reactivity of all the MIPs in 
comparison to normal fertile samples.  When analysing immuno-staining of the MIPs 
in postmenopausal endometrium, Quick Score method was not used, due the limited 
amount of endometrium collected due to the extremely thin endometrium that is seen 
in healthy normal women without any endometrial pathology. Analysis was 
undertaken by assessing the intensity of staining along with descriptive localisation. 
This might have slightly skewed the results obtained when comparing both control 
groups. As results gained were all statistically significant we can still assume the 
results are valid and reliable therefore use it as foundation to plan future work.  
It was difficult to extract RNA from postmenopausal endometrial biopsies due to the 
naturally thin endometrium in this phase resulting in RNA of insufficient quality and 
quantity, therefore the expression of MIPs was not investigated with using RT-PCR. 
This is an important downfall to consider and rectify when planning future work. 
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5.3  ENDOMETRIAL CANCER 
 
 
All four MIPs have been shown to be expressed in breast cancer cells, and since 
similar to breast cancer, endometrial cancer is also an oestrogen dependent cancer it 
was hypothesised that the MIPs would be similarly expressed in endometrial cancer 
cells. 
Results gained from this study agree with the above hypothesis for the MIPs S100A4 
and S100P but not with AGR2 and OPN. Both IHC and RT-PCR have shown that 
endometrial cancer cells highly express S100A4 and S100P, but express less AGR2 in 
comparison to both normal fertile and postmenopausal endometrium. Furthermore, 
the results obtained from the two methods I used (IHC and RT-PCR) were 
contradictory for OPN, with IHC displaying a reduction in OPN expression in 
endometrial cancer cell, and RT-PCR demonstrating increased expression.  
The MIPs may be expressed as a protein, but not necessary in mRNA, as it is less 
stable. The sample size for RT-PCR was too small in comparison with samples 
analysed by IHC (i.e. Two endometrial cancer samples were analysed for RT-PCR 
compared to 30 for IHC). With the RT-PCR we analysed the whole tissue sample 
including all cells (normal adjacent endometrial epithelial, stromal, blood vessel, 
blood cells and cancer cells) but with IHC only analysed an exact single cellular 
compartment of interest. This may be the main reason for the differences seen. The 
exact cellular composition of the frozen tissue biopsy that was used to extract RNA is 
not known so the resulting MIPs expression seen will only be a relative suggestion 
but may not be an exact match to the IHC results.     
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Since the IHC was done on paraffin tissue sections, the secondary confirmatory 
method of RT-PCR would be ideally done on the same biopsy. Some say the high 
level of paraffin in the section may alter the amplification of the DNA. This was 
demonstrated during optimisation of the RT-PCR technique, where S100A4 and OPN 
produced no positive results, despite adding amplification enhancing reagents. AGR2 
and S100P, however, amplified the cDNA adequately using the RNA extracted from 
paraffin section. This may suggest that AGR2 and S100P are more sensitive in being 
locating and amplified in mRNA compared to S100A4 and OPN. RT-PCR is not 
quantitative analysis of the mRNA message; quantitative real time PCR may be a 
more suitable method for this. 
No significant relationship was determined between endometrial cancer FIGO grade 
and expression of the MIPs. A larger sample set may be required in order for 
confirmatory statement on MIPs and FIGO grade correlation to be established.   
 
5.3.a OSTEOPONTIN 
 
Functionally, OPN mediates cell adhesion, chemotaxis, stress-dependent angiogenesis, 
prevention of apoptosis and anchorage-independent growth of tumour cells (Wai & 
Kuo 2004).  
Conflicting results were generated with the two laboratory methods in assessing OPN 
expression. With the large difference in sample size used between the two methods, it 
is difficult to compare them directly. IHC showed a statistically significant decreased 
immuno-reactivity of OPN in endometrial cancer cells compared to normal fertile 
proliferative phase group (Mann Whitney U test; Glandular p=0.0047, Luminal p = 
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0.0018). However compared to postmenopausal control samples, immuno-reactivity 
of OPN was increased (Mann Whitney U test; Glandular p=0.0001, Luminal p < 
0.0001).  
In comparison to postmenopausal endometrium, results suggest that OPN may have 
properties, which aid in endometrial cancer metastasis.  A wider and larger range of 
samples, in particular postmenopausal samples, needs to be examined to assess the 
difference in OPN expression.  
 
5.3.b S100P 
 
S100P has been shown to mediate tumour growth, drug resistance, and metastasis. 
Therefore, S100P is a useful marker for differentiating cancer cells from normal cells, 
which can aid in the diagnosis of cancer by cytological examination. There is 
considerable evidence demonstrating the elevated expression of S100P and tumour 
cell migration in various cancers (Sato & Hitomi 2002; Guerreiro Da Silva et al 2000; 
Beer et al 2002; Torres Schor et al 2006). 
Results showed a statistically significant increased immuno-reactivity and expression 
of S100P in endometrial cancer cells compared to the control groups (Mann Whitney 
U test; N.Fertile Stroma p=0.0007), P.Meno Stroma p >0.0001), therefore concurring 
with previous reports made. 
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5.3.c AGR2 
 
AGR2 has been widely investigated in breast cancer, showing an over expression of 
AGR2 in the cancer cells (Brychtova et al 2011; Liu et al 2005). It has also been show 
to be co-expressed with oestrogen receptor alpha (ER) in breast cancer cell lines and 
clinical specimens (Fletcher et al 2003)  
The substantial evidence demonstrating the link between AGR2 and cancer cell 
migration, invasion and tumour growth lead us to hypothesise that endometrial cancer 
cells would aberrantly express AGR2.  
Results from this study showed a decrease in AGR2 expression in endometrial cancer 
cells compared to normal fertile control group in both IHC and RT-PCR. However, 
the results were not statistically significant (Mann Whitney U test; Glandular 
p=0.1736, Luminal p = 0.1175). In comparison to postmenopausal endometrium there 
was a statistically significant increased immuno-reactivity to AGR2 in endometrial 
cancer cells (Mann Whitney U test; p < 0.0001). 
RT-PCR results also confirmed the IHC results, but the difference observed was not 
statistically significant. This is primarily due to the small sample set used to assess the 
expression of AGR2 mRNA. 
 
5.3.d S100A4 
 
Studies to determine the function of S100A4 have shown that it may play a role in the 
different aspects of tumour progression, including motility, invasion, and apoptosis 
(Garrett et al 2006; Helfman et al 2005; Boye & Maelandsmo 2010). 
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Both IHC (MWU Test; NFertile Stromal p=0.0275, P.Meno Stromal p=0.0004) and 
RT-PCR demonstrated S100A4 to be over expressed in endometrial cancer cells, 
compared to both control groups. This suggests that up-regulation of S100A4 may 
have a direct role in inducing metastasis in endometrial cancer. 
 
5.4  LIMITATIONS 
 
 
As with all research there are limitations within the work carried out for this project. 
A greater sample size, particularly with RT-PCR would have enhanced the data 
generated, increasing the reliability and validity of results. Nevertheless majority of 
the findings have been well demonstrated and statistically significant, despite the 
sample size. 
Quick Score technique was used to semi-quantitatively analyse and compare 
immunohistochemistry attaining for the four MIPs. Taking in consideration of size 
and integrity of each sample, this technique was only applied to analysing the normal 
fertile control and endometrial cancer samples. Due to the sparse amount of intact 
postmenopausal endometrium collected, the samples were subjectively analysed using 
generalised baseline intensity score and descriptive localisation remarks. This would 
undoubtedly lead to some discrepancies with the statistically analysis comparing the 
separate groups, however a generalised comparison was elicited. The analysis 
technique used in future studies would need to be further evaluated to ensure the 
accuracy of results.  
! EE!
Pathology reports determined two endometrial cancers, collected at Liverpool 
Women’s Hospital, as carcinosarcoma. There is controversy over whether you can 
class these as true endometrial cancer. As discussed in Chapter 1.2, studies have 
included this as Type 2 endometrial cancers, but it does raise the point of the whether 
it can be a true comparison to Type 1 and Type 2 endometrial cancers. Likewise for 
the mixed endometrial carcinomas, one is not entirely sure which areas they are 
analysing, serous or endometrioid. Can the results be used to compare with a true 
endometrioid endometrial cancer? Ideally with a larger and wider range of samples, 
the groups could be split and individually compared to get an accurate and more 
reliable comparison. 
Tissue samples used for the RT-PCR would need to be evaluated and considered 
when analysing results. The endometrial biopsy collected undoubtedly contains 
amounts of blood, mucus and myometrium from full thickness samples, and from the 
naked eye it is hard to distinguish what part of the biopsy has been included in the 
analysis.  
 
5.5  FURTHER WORK 
 
 
Further work is necessary to obtain more detailed an accurate results. Laser capture 
micro-dissection of specific endometrial cancer cells can be undertaken to ensure that 
RNA is only extracted from cells of interest, for example dissected endometrial 
cancer cells. 
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Obtaining samples of endometrial metastatic lesions would be ideal in assessing the 
expression of the MIPs while comparing it to endometrial cancer cells in the 
endometrium. When analysing the demographic and patient data, it was clear that 
majority of the patients were diagnosed with early stage cancer (50% FIGO Grade 1 
for endometrioid endometrial cancer and 76% FIGO Stage I all endometrial cancer). 
The number of women seen with metastatic endometrial cancer is low, additional 
surgery is not the primary treatment for high grade/stage cancers. Therefore obtaining 
samples of endometrial metastatic lesions is a challenge, practically and ethically.  
Further laboratory techniques, including quantitative real time RT-PCR and Western 
blotting should be done to confirm the results gathered from immunohistochemistry. 
Long-term follow up of endometrial cancer patients would also allow for a detailed 
assessment of progress of the cancer. 
Functional studies of in-vitro primary endometrial cancer cells or endometrial cancer 
cell lines need to be undertaken for reproducibility. We have successfully cultured 
and maintained the growth of an endometrial cancer sample in our laboratory, 
producing a primary endometrial cancer cell line. See Fig 44.  
Using these cells we can further investigate the role of the four MIPs and investigate 
the function of MIPs in live cells in culture (in vitro). For example we can inhibit 
MIPs expression (by silencing MIPs gene expression using techniques such as short 
interfering RNA (siRNA)) of cultured primary endometrial cancers and then assess 
the changes in the invasive / migratory potential of those cells in vitro to confirm the 
function of MIPs in the metastatic process. Furthermore established cell lines can be 
also be utilised to investigate the MIPs further in established invasion, adhesion assay 
systems and also by xenografting such cell lines in immune-compromised mice. 
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At the moment we cannot say whether MIP expression is a causative (essential) or 
resultant effect of endometrial cancer. This question however, can only be answered 
in future in vitro studies using direct transfection of expression vectors for the MIPs 
into endometrial caner cell lines and testing for the ability of the resultant 
transfectants to produce endometrial cancer lesions in syngenic animal models. 
It has been shown that endometrial cancer cells have a small, specialised population 
of cancer stem/progenitor cells (CSCs) and these are speculated to give rise to distant 
metastasis (Hubbard et al 2009). We are therefore currently assessing the expression 
of cell fate markers CD133, CD138 and Telomerase in endometrial cancer. These cell 
fate markers regulate the survival ability of the endometrial cells, contributing to 
endometrial cancer tumorigenicity, pathology, hence the metastatic process (Wu & 
Wu 2009; Rutella et al 2009; Kodama et al 2005; Kyo et al 1997; Brien et al 1997). 
 
Figure 44: Phase micrograph of endometrial cancer (Courtesy of AJ Valentijin) 
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5.6  SUMMARY 
 
 
Overall the data from this project provides an interesting insight into the metastatic 
process of endometrial cancer. Our results suggest that all four MIPs play a key role 
in metastasis of endometrial cancer. Further research is required to understand the 
extent of the involvement OPN, S100P, AGR2 and S100A4 in inducing the metastatic 
process. 
As one of the most common gynaecological malignancies, and the increasing 
incidence and mortality rates, it is important to create a non-invasive and reliable 
assay of detecting endometrial cancer early. With further advanced research these 
four MIPs could play a pivotal role in providing very useful diagnostic markers for 
endometrial cancer.  
 
 
 
 
 
 
 
!
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7.3 STANDARD OPERATING PROTOCOLS !!
7.3.a SAMPLE RECEPTION: PROCESSING ENDOMETRIAL 
BIOPSIES 
 
BACKGROUND 
The SOP will describe the protocol for the fixation of endometrial biopsy samples in 
10% neutral buffered formalin and preparation of frozen blocks in liquid nitrogen. 
The SOP will also briefly describe the archive arrangements for the sample and 
patient information. 
 
HEALTH AND SAFETY REQUIREMENTS 
Laboratory workers should be immunised against hepatitis B before commencing 
work with human material (refer to the University of Liverpool code of practice on 
immunisation available from the departmental safety coordinators office). Laboratory 
coats and nitrile gloves should be worn at all times when handling the unfixed 
biopsies. All manipulations on the fresh samples should be performed in the class II 
microbiological safety cabinet situated in room 1124.  
 
Care should be taken when dealing with dry ice and liquid nitrogen due to risks of 
burns and asphyxiation. The researcher should work in a well-ventilated room and 
wear personal protection equipment including thermal gloves and full safety face 
shield. Refer to the endometrial sample reception risk assessment and the specific 
COSHH forms for further information. Guidelines on the use of cryogenic substances 
are also available from the physical hazards code of practice on the University of 
Liverpool health and safety intranet: 
https://www.liv.ac.uk/intranet/safety/codes_of_practice/physical_hazards.pdf 
 
In the event of a biological spillage onto the skin, sharps or burn injury, wash 
immediately with cold running tap water. Seek immediate advice from the designated 
first aider and report the incident to the Departmental Safety Coordinator within 24 
hours.  
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EQUIPMENT INFORMATION: 
• Dry ice, Virkon and laboratory plastics (e.g. universals etc) are purchased from 
Liverpool Women’s Hospital (NHS) purchasing department.  
• Nunc cryotubes are purchased from Corning.  Distributor address: PO Box 
75089, 1117 ZP Schiphol, Koolhavenlaan, The Netherlands. 
• Forceps and scissors are supplied by Raymond A Lamb Ltd. Manufacturer’s 
address: Units 4 & 5, Parkview industrial estate, Eastbourne, East Sussex, BN23 
6QE England. 
• TriGene Advance is obtained from Medichem International. Supplier address: 
PO Box 237, Seven Oaks, Kent, TN15 0ZJ. Telephone: 01732 763555. 
• Neutral Buffered Formalin solution is purchased from Sigma Aldrich. Supplier 
address: Fancy road, Poole, Dorset, BH12 4QH. Telephone 01202 712300. 
• Biomat2 Recirculating microbiological safety cabinet was purchased from 
Bioquell. Supplier information: Walworth road, Andover, Hampshire, SP10 
5AA. 
• Cool Jet Instant Freezing Aerosol purchased from Raymond A Lamb. Supplier 
information: Units 4 and 5 Parkview Industrial Estate, Eastbourne, East Sussex, 
BN23 6QE England. Telephone 01323737000 
 
METHOD: 
A Laboratory Preparation: 
1 Lift glass shield of microbiological safety class II (MCII) cabinet until edge is 
level with the second notch marked on the cabinet frame. Press and hold down 
the “ON” button until the MCII cabinet switches on. Press       and hold down 
to switch on light.  
2 Clean the surfaces of the MCII cabinet with 1% TriGene Advance solution 
and dry with absorbent towels. 
3 Place the following items on a clean plastic tray in the MCII cabinet: 
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• Universal tube containing phosphate buffered saline (PBS) and tissue. Tube 
should be labelled with the date and the specimen ID number. 
• Small weighing boats 
• Forceps and scissors 
• Discard pot containing 1% Virkon solution. 
• Equipment decontamination container (small plastic container filled to 
approximately 50% capacity with 2% TriGene Advance Solution). 
4 A box of dry ice should be placed on the adjacent bench.  
5 Label a Nunc cryotube with the specimen ID number and date. 
6.  Place the labelled cryotube and a clean pair of forceps in the box of dry ice to 
cool. 
 
B Biopsy Processing Procedure: 
In theatre endometrial tissue is obtained via pipelle sampling or full thickness 
endometrial biopsies. After biopsy tissue sample should be adequately distributed in 
the following tubes: 
1. neutral based formalin (NBF)  
2. PBS 
3. culture media  
4. RNA later solution 
 
1 All tubes except for tube 1 should be placed immediately into crushed ice. 
Transport sample collection box to room 1124. Transport of human samples 
within the hospital should follow the University and Liverpool Women’s 
Hospital Trust safety guidelines (refer to transport SOP for more information).  
2 Store tube 1 under fume hood located in room 1125. Tissue in NBF tube 
should be left for 24 hours for next day processing. If the sample is collected 
on a Friday then the NBF pot should be stored in the sample reception fridge 
in room 1124 to minimise evaporation.  
3 Tubes 3 and 4 should be placed in the refrigerator located in room 1124.   
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4 Transfer tube 2 to the MCII cabinet.  
5 Place equipment decontamination container under hood. 
6 Prepare box of dry ice and place in cabinet. Dry ice box should contain opened 
cryotube and forceps. 
7 Transfer tissue from tube 2 to a weighing boat using a second pair of forceps. 
Carefully remove mucous and blood clots from the tissue and place waste in 
the 1% Virkon discard pot. 
8 Using a non-sterile plastic pipette transfer 1% virkon to tube 2 containing 
remaining PBS for overnight decontamination  
9 Manipulate the sample in the weighing boat so that it is coiled into a ‘Danish 
pastry’ shape with forceps. Discard used forceps in equipment 
decontamination container containing 2% trigene.  
10 To freeze sample, place weighing boat on dry ice and using cool jet aerosol 
spray the top part of tissue sample until frozen. To loosen tissue sample in 
weighing boat rub bottom surface of weighing boat.   
11 Transfer the tissue into the labelled cryotube using the pre-cooled forceps and 
replace lid. Discard second used forceps in equipment decontamination 
container when finished.  
12 Place cryotube in the next available slot in the Nalgene storage boxes in 
freezer 3 (stack A, shelf 3 of the –800C Sanyo freezer situated in room 1127).  
13 Enter the specimen ID number and date into the box plan in the freezer file 
(black ring binder held in room 1127). 
14 Update the sample reception log (in room 1124). Enter sample ID, date and 
name of person processing samples. Enter information according to Good 
Clinical Laboratory Practice (GCLP) guidelines.  
15 Complete both portions of the Biopsy request form, held in the RM Biopsy 
Log Ring binder. Enter patient ID number, specimen code, number of tissue 
pieces and sample storage location.  
16 Detach top portion of the Biopsy request form and staple to the photocopied 
consent form. Forms are then placed into the locked filing cabinet in room 
1127.  
17 Original consent form is held by Dr Dharani Hapangama. 
 
! (FE!
7.3.b SAMPLE RECEPTION: PROCESSING BLOOD SAMPLES 
 
HEALTH AND SAFETY 
Gloves should be worn whenever handling biological samples. Refer to COSHH and 
local guidelines before commencing with procedure. 
BACKGROUND 
Whole blood and serum collection is vital to gain information about oestrogen and 
progesterone hormone concentrations. Together with histological dating and the LMP 
this will allow an accurate detection of what time in the ovarian cycle the participant 
is in.  
In is important to handle blood samples under the microbiological safety cabinet in 
lab 3 for protection against potentially hazardous micro-organisms.   
EQUIPMENT INFORMATION 
1. Dry ice, Virkon, blood bottles and laboratory plastics (e.g. pastettes) are 
purchased from Liverpool Women’s Hospital (NHS) purchasing department.  
2. Nunc cryotubes are purchased from Corning.  Distributor address: PO Box 
75089, 1117 ZP Schiphol, Koolhavenlaan, The Netherlands. 
3. TriGene Advance is obtained from Medichem International. Supplier address: 
PO Box 237, Seven Oaks, Kent, TN15 0ZJ. Telephone: 01732 763555. 
4. Biomat2 Recirculating microbiological safety cabinet was purchased from 
Bioquell. Supplier information: Walworth road, Andover, Hampshire, SP10 
5AA. 
5. Hermle Z216MK Refrigerated Microcentrifuge purchased from Progen 
Scientific 
A division of G.H.Zeal Ltd. Zeal House 8, Deer Park Road, Merton, London, 
SW19 3UU 
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METHOD 
1. Collect 2.7ml of blood in a pink EDTA tube, and 4.7mls of blood in a gold 
serum tube for plasma serum. 7.5mls of blood can be pre-collected in a 10ml 
syringe first and then distributed into the appropriate opened blood bottles. 
Replace the bottle cap and immediately invert both bottles 5 times.  
2. Once obtained, immediately place both tubes in crushed ice until blood 
samples are transported to the labs, in room 1124. 
3. Once transported into the lab, leave serum blood bottle to stand for at least 30 
mins in refrigerator before centrifuging. Foam containers should be available 
to keep serum blood bottles in an upright position.  
4. Unscrew lid to pink blood bottle. Using a blue -1000µl pipette, transfer whole 
blood from pink tube into two labelled cyrotubes (no centrifuging required). 
Replace cyrotube lids and place into dry ice box. Eject blue pipette tip into a 
container containing 2% virkon. 
5. After 30 minutes, centrifuge serum blood tube at 3,000 rpm for 10 min at 4ºC. 
Please refer to Standard Operating Protocol 36 for “Use of the Hermle 
Z216MK Refrigerated Microcentrifuge”.  
6. Once centrifuged, carefully remove the sample bottle from the centrifuge 
machine in order to leave the layers undisturbed.  
 
 
7. Place a clean blue tip on the pipette, remove the lid from the serum tube and 
carefully aspirate the serum plasma, distributing it to two labelled cyrotubes. 
Remove as much as possible, taking care not to disturb the buffy coat at the 
interface between the red cells and the plasma. Place cyrotubes into dry ice 
box. 
8. Eject the blue pipette tip to a container containing virkon. 
9. Cyrotubes should be labelled with: 
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• Specimen ID 
• Contents, i.e. “whole blood” or “serum” 
• Date obtained.   
10.  Carry dry ice box to room 1127 and place into the appropriate sample boxes 
in the -70°C freezer and record its exact location in the freezer file and fill 
blood sample forms.  
11. Using a pastette transfer 2% virkon into both used blood bottle for disinfection 
purposes, and dispose blood bottles into clinical waste bin. 
12. Clean fume hood after use using trigene spray.  
 
 
 
7.3.c TISSUE PROCESSING 
 
 
BACKGROUND 
Formalin fixed tissue is dehydrated, cleared then impregnated with paraffin wax using 
the automated Shandon Citadel 1000 processing machine. The processing setting for 
most sample types is programme A which operates using the schedule provided 
below. The total processing time is 18 $ hours, therefore the processor is generally 
run overnight. Starting the processor at 2pm will result in completion of the cycle at 
8:45 the following morning. 
 
Programme A Processing Schedule: 
 
4% formalin in neutral buffer 45 minutes 
60% Ethanol 1 hour 
70% Ethanol    1 hour 
90% Ethanol     1 hour 
100% Ethanol    1 hour 
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100% Ethanol   1 ! hours  
100% Ethanol   2 hours 
Xylene 1   1 hour  
Xylene 2   1 ! hours  
Xylene 3   2 hours 
Wax 1   2 ! hours  
Wax 2   3 ! hours 
 
EQUIPMENT  INFORMATION: 
Citadel processor (serial number CA 1390 EO 608) manufacturer: Thermo electron 
Corporation. Manufacturer’s address: 93 – 96 Chadwick Road, Astmoor, Runcorn, 
Cheshire, WA7 1PR England. 
MAINTENANCE (CONTRACT AND SERVICING INFORMATION) 
Maintained/serviced by Thermo Fisher Scientific 93 – 96 Chadwick Road, Astmoor, 
Runcorn, Cheshire, WA7 1PR England. Tel: 01928 562 541, Fax: 01928 562 512. 
SOLVENT INFORMATION: 
Ethanol and xylene are purchased from Chemistry solvent stores (University of 
Liverpool). The wax (Histoplast PE REF8330) is purchased from Thermo Scientific 
93 – 96 Chadwick Road, Astmoor, Runcorn, Cheshire, WA7 1PR England.  The 10% 
neutral buffered formalin is purchased from Sigma Life science, Fancy Road, Poole, 
Dorset, BH12 4QH. 
HEALTH AND SAFETY PRECAUTIONS: 
Wear a laboratory coat, safety spectacles and nitrile gloves. Xylene and formalin are 
harmful by contact to skin and eyes or if ingested or inhaled. Refer to the risk 
assessments and COSHH forms before starting procedure. 
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Overnight processing procedures requires the completion of permits provided in 
safety circular SCR14/3 (link to document provided below). A ‘Yellow permit’ (for 
long term operation) should be prepared by the DSC or laboratory manager and the 
copy secured in a clear plastic folder on the door outside laboratory 4. The ‘Pink’ 
permit (valid for the duration of the experiment only) should be prepared by the 
processor user and the document should be placed on or adjacent to the apparatus. 
Information that needs to be recorded on the pink copy includes: 
a) experimental details 
b) times and dates of experiment 
c) emergency procedures 
d) name, address and telephone number of the processor user 
e) signature of researcher concerned and a countersignature from the laboratory 
manager/DSC. 
 
PROTOCOL 
A Preparation of Solvent Containers on Processing Machine: 
Between processing runs, ethanol solutions are stored in labelled bottles to prevent 
evaporation. These are found in the metal solvent cabinet under the bench in 
Laboratory 4. Therefore the solvent containers must be re-filled before tissue 
processing commences. To access the processor solvent container, press the raise 
button on the hand held controller. Remove the evaporation covers from the top of the 
processor then press rotate or check/fill button. The rotate function will cause the 
operating head assembly to advance one position and the check/fill option rotates the 
head three positions. Remove the container using the metal handles and add 1.5L of 
the required ethanol solution (the top of the bevelled edge on the solvent container is 
approximately 1.5L). Repeat process until all ethanol containers are filled. It is also 
advisable to check the level of the xylene, formalin and the wax containers on a 
regular basis. If fresh 100% ethanol is used to top up or prepare solutions for the 
processor ensure the ethanol log is updated with the volume used. The ethanol log is 
situated in DSC office (room 1128).  
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B Sample Processing Procedure 
1. Label plastic cassettes with the sample ID number using pencil. 
2. Carefully remove the tissue from the formalin pot using forceps and place into 
the small wire inserts. Secure the inserts into the plastic cassettes and re-check 
the sample ID. Dispose of the used formalin in the red labelled waste container 
which is stored below the fume hood. 
2. Arrange the cassettes so they are loosely spaced in the processing baskets 
3. Press Go To 1 on the hand held controller, slot the processing baskets onto the 
holder over the formalin and place weight on top of the basket. 
4. Press Lower button on the hand held controller (to lower the basket into the 
formalin). 
5. Check the time is correct by pressing clock (alter time by pressing the + button 
or whilst holding in the clock button if necessary). 
6. Select the appropriate processing time function: 
 
Date of 
Processing 
Processing 
Time 
Hand Held Controller Action 
Monday-Thursday Before 2pm Press delay on button 
Monday-Thursday After 2pm Press autostart button 
Friday Before 2pm Press days delay, hold this in, scroll to 2 days using the + 
button then press delay on. 
Friday After 2pm press days delay, hold this in, scroll to 1 day using the + 
button, then press delay on 
 
7. Complete the citadel 1000 user log (the folder is situated by the embedding 
staition in laboratory 4) with sample, solvent and programme information.. 
8. When the processing cycles are completed, switch on the Shandon Histocentre 
3 embedding machine. 
9. Press raise button on the hand held controller and remove baskets from holder. 
10. Place blocks into heated reservoir in the embedding machine. 
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11. Wipe processing baskets with absorbent towels to remove surplus wax then 
place equipment into the oven (heated to ~100°C) for several minutes to 
remove any residue.  
12. Soak biopsy inserts in xylene for several hours/overnight to remove wax 
residues. Leave the inserts in the fume hood to air dry  
13. Remove the alcohols from the processing machine using the method described 
in section A and pour solutions in the labelled storage bottles using a funnel. 
The storage bottles are then placed in the flammable solvent metal storage 
cabinets.  
14. Update the citadel 1000 processing user log.  
 
C Disposal of Waste Solvents 
The solvents must be changed on a regular basis (depending on time of year and 
processor usage) to ensure efficient processing of the tissue samples. Waste solvents 
must be placed in the red solvent waste containers and identified clearly with the 
appropriate labels provided by Lisa Heathcote or Jo Drury. Contaminated waste wax 
can be discarded by pouring the molten solution into a container and cooling until the 
wax is set. The wax container can then be disposed of in the LWH clinical waste. 
Refer to the waste disposal protocol (SOP 25) for further information. 
 
 
7.3.d EMBEDDING SAMPLES 
 
 
BACKGROUND 
The Shandon Histocentre provides easy convenient embedding of histological 
specimens. Prior to operating the unit, be sure to read and observe the safety 
instructions in the operator manual. 
 
EQUIPMENT INFORMATION: 
Plastic cassette 
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Shandon HistoCentre 3 Embedding Station 
Hot forceps 
Metal Moulds  
HEALTH AND SAFETY REQUIREMENTS 
Normal laboratory precautions, including the wearing of gloves, laboratory coat, 
safety goggles and the use of a fume cupboard, should be taken when handling the 
samples. Refer to the risk assessments and COSHH forms before starting procedure. 
Place all waste in clinical waste bin. 
METHOD: 
 
1. When the processing cycles are completed, switch on the Shandon 
Histocentre 3 embedding machine. 
2. Press raise button on the hand held controller and remove baskets from 
holder (use paper towels to ensure that wax doesn’t drip on the floor). 
3. Place blocks into heated reservoir in the embedding machine. 
4. Wipe processing baskets with absorbent towels to remove surplus wax 
then place equipment into the oven (heated to ~100°C) for several minutes 
to remove any residue. 
5. Take a metal mould from the heated unit, place it underneath the wax tap 
and half-fill it with wax. 
6. Take a cassette and place on the heated area by the wax tap to prevent 
solidification of the wax. 
7. Open the cassette, and transfer the sample to the wax-filled mould using 
hot forceps. 
8. Move the mould to the “cold spot” at the front of the dispensing unit 
9. Position tissue to bottom surface of metal mould using hot forceps to 
stabilise tissue in place.  
10. Cover with a plastic cassette (number upwards) and hold in place by 
applying pressure with hot forceps on top of cassette.  
11. Top up wax by hovering above the heated area and place on pre-cooled 
cooling block. 
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12. Using forceps tap against top of plastic cassette to release any air bubbles 
within the liquid wax. 
13. Leave on cooling area* for at least 30 minutes 
14. Cassette should come cleanly away from the metal mould.  If necessary 
use forceps or a scalpel to loosen the edges. 
15. Store the block in the metal storage cabinet (trays 5 and 6) in numerical 
order (room 1125). 
16. Place the metal biopsy inserts into a container of xylene to clean off the 
wax. 
 
 
 
7.3.e CUTTING PARAFFIN SECTIONS 
 
BACKGROUND 
Preparation of 3-5 micron thick sections from wax – embedded tissue is a commonly 
used histological technique. This SOP will describe how to prepare these using the 
Microm HM335 rotary microtome and attaching sections onto aminopropyl triethoxy 
silane (APES) coated slides. 
 
HEALTH AND SAFETY REQUIREMENTS 
Wear a laboratory coat and nitrile gloves. Care needs to be taken when performing 
this procedure because there is a risk of sharps injury from the microtome blades. 
Refer to the physical hazards safety circular, risk assessments and COSHH forms 
before starting procedure. Also ensure waste wax sections are cleaned from the floor 
and the general working area at the end of the procedure to prevent risk of slip/trip 
injuries. Place all waste tissue sections in the clinical waste bags and the used 
microtome blades and slides into the yellow clinical waste sharps bins. DO NOT 
COMMENCE WORK WITH THE MICROTOME UNTIL SUFFICIENT 
TRAINING HAS BEEN PROVIDED AND AUTHORISATION HAS BEEN 
RECEIVED FROM LISA HEATHCOTE OR JO DRURY. 
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EQUIPMENT INFORMATION: 
• Microm HM335 rotary microtome is supplied by MICROM Company. 
Manufacturer’s address: Microm UK Ltd., 8 Thame Park Business Centre, 
Leinman Road, Thame, OX9 3XA. Further information can also be obtained on 
http://www.microm-online.com. 
• Microscope slides (twin frost size 26 x 76mm-Printed “IVD CE” 90º ground 
edges, catalogue number MAE-1000-03P Pack of 1000) are purchased from 
Liverpool Women’s Hospital (NHS) purchasing department.  
• Coverslips 22 x 22mm, 22 x 40mm and 22 x 50 are purchased from Liverpool 
Women’s Hospital (NHS) purchasing department. 
• Microtome blades (MB Dynasharp Catalogue Reference 3050836) are 
purchased from Thermo Scientific 93 – 96 Chadwick Road, Astmoor, Runcorn, 
Cheshire, WA7 1PR England. 
• Forceps, paint brush, section dryer and water bath are supplied by Raymond A 
Lamb Ltd. Manufacturer’s address: Units 4 & 5, Parkview industrial estate, 
Eastbourne, East Sussex, BN23 6QE England. 
 
METHOD: 
1. Carefully fill the water bath with distilled water ensuring the electrical 
connection points remain dry.  
2. Turn on water bath from the plug and set the power switch from O to I 
3. The water will need to be heated to 40°C. The best way do to this is to first turn 
the temperature dial to 10 (maximum setting) for 7-8 minutes and then turn the 
dial down to 2.5. If the temperature of the bath is above 40°C, pour in distilled 
water to lower the temperature.  
4. Scrape away any surplus wax from the edges of the cassette to ensure a good fit 
in the holder then place the tissue block in the refrigerator. Cool the block for at 
least 30 min prior to cutting. 
5. Ensure that the handwheel is locked in the upper range of the vertical movement 
by turning the lever downwards.  
6. Press the reverse course feed button          to move the knife carrier away from 
the specimen. 
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7. Turn the clamping lever on the blade holder to the front and swing the 
protective bracket forwards. Insert the feather S35 blade into the slot behind the 
clamping plate ensuring the blade is level on the rail (use forceps to manipulate 
the blade if necessary). Use half of the blade for cutting at a time. Preferably use 
left side first and then the right side.  
8. Return the clamping lever to the original position (in line with the black frame 
of the blade) to lock the blade in place. The protective bracket should also be 
returned to the original position when the microtome is not in use to minimise 
the risk of sharps injury.  
9. The blade angle is pre-set to 10-12° and should not require adjustment. These 
settings should remain the same to ensure minimal amounts of tissue are wasted 
when different laboratory workers prepare sections from the same block.  
10. Insert the specimen against the ‘fixed jaw’ of the universal cassette clamp and 
secure by pulling the lever to the front. Ensure that each specimen cassette is 
always inserted in the same orientation (horizontal placement in the universal 
cassette clamp with the specimen number on the left) and inserted to the far left 
of the clamp.  
11. Unlock the handwheel by turning the lever upwards. Rotate handwheel in a 
clockwise direction until the centre of the tissue block is level with the blade 
holder. Then lock the handwheel by turning the lever downwards.  
12. Press the forward course feed button          to move the blade carrier near to the 
specimen. To establish whether the blade is close to the specimen view the 
distance between the two at a side angle. Also, gently move the handwheel up 
and down to see if the specimen is not touching the blade. When you are 
satisfied that both blade and specimen are close to each other move the 
handwheel so the specimen is away from the blade, this prevents scoring the 
specimen block in the middle. 
13. The required section and trimming thickness are set by means of a circular knob 
on the left of the instrument. Press the circular control knob to switch between 
section (FEED) and trimming (TRIM) thickness. The corresponding LED will 
be displayed on the operating control panel:  
• Green LED lights up when the FEED function is used 
• Yellow LED lights up when the TRIM function is selected. 
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14. When a new tissue block is used, select TRIM and turn the control knob until 
the corresponding LED is set at 20%m. 
15. Unlock the handwheel and start trimming by rotating the handwheel in a 
clockwise direction. Once you begin to see specks on tissue in the sections 
change the TRIM settings from 20%m to 10%m.  
16. Continue to trim on the new setting until a representative amount of tissue is 
exposed in the tissue block. 
17. Select FEED and turn the control knob until the corresponding LED is set at the 
required section thickness (usually 3-5%m). Rotate the handwheel until the first 
section generated. Gently hold the end of the section with forceps and continue 
to cut until a ribbon (consisting of approximately 6 sections) is produced. 
Discard the first few sections when first cutting on the feed section as usually 
the first few are too thick.  
18. Carefully float the sections onto the pre-warmed water bath. Leave or a minute 
or so until the wrinkles in the section disappear. Separate the sections by 
applying gentle pressure using forceps. Select the best sections and float onto 
APES-coated slides. It is considered to be good laboratory practice to attach 
each section in the same orientation on the surface of the slide where you can 
read the IVD sign.  
19. Label the frosted part of the slide with the specimen ID and thickness (using a 
pencil). Place slides in a rack to dry at room temperature for several hours 
(preferably over night).  
20. When not cutting for a few minutes the specimen block moves slightly out of 
place which potentially can create thicker sectioning when you go back to 
cutting. To avoid creating thicker sections press the reverse course feed button         
very slightly to move the knife carrier away from the specimen by a small 
amount.  
21. During the cutting procedure a build up of wax on either side of the blade 
carrier. This can potentially cause scoring of the section. Using a soft brush, 
brush in an upward direction against the blade carrier to remove the wax, this is 
to prevent blunting of the blade and cutting down of the brush if a downward 
direction was used.  
22. If the sections start to wrinkle during the cutting procedure, then the tissue block 
has become too warm and needs to be refrigerated for at least 10 minutes. To 
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remove the tissue block, press the reverse course feed button until the specimen 
is safely away from the blade holder. Return the safety bracket to the upright 
position. Remove the tissue block by pressing the lever on the universal cassette 
clamp. 
23. Remove any unused tissue sections from the water bath surface using kitchen 
roll. 
24. When the microtome blade needs to be replaced, return the tissue block to the 
furthest position using the course feed button and lock the handwheel. Unlock 
the lever on the blade carrier and place the microtome blade into the yellow 
clinical waste sharp bin. NEVER try to remove the microtome blade when the 
tissue block is close to the blade edge because there is a risk of sharps injury 
and also the risk of damaging the tissue block. 
25. When the sections have dried, place the slides into a staining rack and bake for 
60 minutes in a slide drier (pre-warmed to 60°C), or 37º C overnight. Place 
slides in a suitable ‘dust free’ container until required for the 
immunohistochemical staining procedure. 
 
 
7.3.f ANTIGEN RETRIVAL 
 
 
BACKGROUND  
The mechanisms of formalin-fixation have been thought to be due to the formation of 
cross-linking bonds between tissue proteins, stabilising them to withstand subsequent 
processing (Mason and O’Leary 1991). The formation of cross linking bonds may, 
however mask the antigenic sites, thereby producing weak or false negative staining 
during immunohistochemical detection of certain proteins. The citrate based solution 
used in this procedure is designed to break the protein cross-links, therefore 
unmasking the antigens and epitopes in formalin-fixed and paraffin embedded tissue 
sections, thus enhancing subsequent staining intensity of antibodies.  
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HEALTH AND SAFETY REQUIREMENTS 
Care needs to be taken when performing this procedure because there is a risk burns 
from the hotplate and pressure cooker. There is also a risk of chemical burns from 
sodium hydroxide and there is a mild irritant effect from citric acid. Suitable personal 
protection equipment (Nitrile gloves, safety glasses and a lab coat etc) should be worn. 
Refer to the physical hazards safety circular, risk assessments and COSHH forms 
before starting procedure. DO NOT COMMENCE WORK WITH THE PRESSURE 
COOKER UNTIL SUFFICIENT TRAINING HAS BEEN PROVIDED AND 
RECEIVED AUTHORISATION FROM LISA HEATHCOTE OR JO DRURY. THE 
SEAL ON THE PRESSURE COOKER SHOULD BE INSPECTED PRIOR TO 
EVERY USE AND REPLACED ANNUALLY. 
EQUIPMENT INFORMATION:  
• Sodium Hydroxide pellets and citric acid are supplied by VWR International 
Ltd, Poole, BH15 1TD England (Future orders will be obtained from Sigma or 
Thermo Fisher).  
• Tefal Clipso Easy 6L pressure cooker and Russell Hobbs hotplate are obtained 
commercially from John Lewis department store. Annual Insurance check TBC. 
The seal/gasket needs to be replaced annually. Gasket (part number SA793145) 
is obtained directly from: http://www.homeandcook.co.uk  refer to section 
accessories/pressure cookers. 2010 price £8.50 +£1.50 delivery 
• Slide racks are supplied by Raymond A Lamb Ltd. Manufacturer’s address: 
Units 4 & 5, Parkview industrial estate, Eastbourne, East Sussex, BN23 6QE 
England. 
 
METHOD: 
• Prepare a 10mM solution of citrate buffer, pH=6.0 by adding 3.15g citric 
acid to 1.5 litre of distilled water.   
• Adjust pH to 6.0 with 2M NaOH. 
• Remove covering lids off hotplate and turn on the hotplate to “6”. 
• Place citrate buffer in the pressure cooker and place lid back on pressure 
cooker. Bring the buffer to a rolling boil. 
! (*F!
• Immerse the slide rack in the buffer using long forceps. 
• Engage the lid, turn the valve to pressure symbol and press the lid down 
until it clicks. 
• Set timer for 1 minute, when steam starts to vent, start timer. After 1 minute, 
turn off the hotplate and release the pressure by turning the vent to the 
“steam” symbol, and cool as quickly as possible by transferring the pressure 
cooker to the sink and running cold water. 
• Transfer the slides back to the glass staining jar containing distilled water. 
• Transfer to TBS ensuring that the tissue does not dry out. 
 
7.3.g IMMUNOHISTOCHEMISTRY 
 
 
Background 
Immunohistochemical staining is a valuable tool for detecting specific antigens in 
tissues. In order to perform the standard staining procedure, first the tissue section has 
to be prepared (SOP 04, 05 and 06), deparaffinized and then rehydrated (SOP 08). 
Antigen retrieval (SOP 09) is then performed to break any protein cross-links, 
therefore unmasking the antigens and epitopes in the tissue sections. The 
DakoCytomatation EnVision+ System, HRP is a two-step Immunohistochemical 
staining technique. This system is based on an HRP labelled polymer which is 
conjugated with secondary antibodies. The labelled polymer does not contain avidin 
or biotin. Consequentially non-specific staining resulting from endogenous avidin-
biotin activity in liver, kidney, lymphoid tissues and cryostat sections is eliminated or 
significantly reduced. The interpretation of any positive staining or its absence should 
be complemented by morphological and histological studies with proper counts. Any 
endogenous peroxidase activity is quenched by incubating the specimen for five 
minutes with Peroxidase block. The specimen is incubated with an appropriately 
characterised and diluted mouse primary antibody, followed by incubation with the 
labelled polymer, using two sequential 30-minute incubations. Staining is completed 
by 10 minute incubation with 3’3-Diaminobenzindine (DAB)+ substrate - chromogen  
which results in a brown – coloured precipitate. 
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Definition 
This SOP will explain how to stain endometrial cells using the anti CD56 antibody. 
Please read entire procedure before staining sections. Perform all antibody and 
staining incubations in a humid chamber and do not allow sections to dry out. Isotype 
and system controls should also be run. Carefully time all tests. Do not touch test 
specimens on slides during the staining procedure, and ensure the slides do not dry 
out during the staining protocol. 
Health and Safety Precautions 
The main health and safety risks to this procedure arise from chemicals/reagents that 
are potentially hazardous, such as hydrogen peroxide (H2O2), xylene, ethanol, and 
DAB (3’3-Diaminobenzindine).  Gloves must always be worn when working with 
any of these chemicals.  
EQUIPMENT INFORMATION 
Staining dishes 
Humidified chamber 
Cover slips 
General points: 
Ensure that solutions cover the whole specimen – if necessary use a piece of Parafilm 
to spread. 
Antibody information: 
Antigen Antibody /cat# Company Dilution duration 
CD56 NCL-L-CD56-
1B6  
Novocastra 1:100 60 mins 
Mouse IgG 
Negative 
Control 
MCA928  Serotech 1:100 60 mins 
 
METHOD (Paraffin sections): 
1. Place slides in a staining dish containing TBS and incubate 5 minutes at room 
temperature. 
2. Prepare 0.3% H2O2/TBS (2.5 ml 30% H2O2 + 247.5 ml TBS) 
! (**!
3. Incubate slides in 0.3% H2O2/TBS bath 10 minutes at room temperature. 
4. Prepare humidified chamber by placing folded paper towels in the centre 
gulley’s and soaking with distilled water. 
5. Tap off any remaining solution, carefully wipe around the specimen and the 
back of the slides with a tissue to remove excess liquid. 
6. Place slides in a staining dish filled with TBS and incubate 5 minutes at room 
temperature. 
7. Tap off any remaining solution, carefully wipe around the specimen and the 
back of the slides with a tissue to remove excess liquid. 
8. Mark area to be stained with DAKO hydrophobic marker pen ensuring that the 
tissue is surrounded with sufficient space to allow spreading of antibodies. 
9. Place slides in a staining dish filled with TBS and incubate 5 minutes at room 
temperature. 
10. Prepare antibody diluent (TBS/0.5 % BSA eg. 250 %l 10% BSA + 4750 %l 
TBS) 
11. Prepare 1:100 dilutions of each antibody, allowing 50 %l per section. 
12. Tap off any remaining solution, carefully wipe around the specimen and the 
back of the slides with a tissue to remove excess liquid. 
13. Place in humidified chamber. 
14. Apply 50%l of the appropriate antibody to each section, spread with parafilm 
to ensure that the entire section is covered and incubate 60 min room 
temperature. 
15. Tap off the antibody solution onto paper towels prior to placing the slides in a 
staining dish filled with TBS. 
16. Incubate 5 minutes at room temperature. 
17. Decant TBS and refill. 
18. Incubate 5 minutes at room temperature. 
19. Tap off any remaining TBS, carefully wipe around the specimen and the back 
of the slides with a tissue to remove excess liquid. 
20. Return slides to the humidified chamber and apply 1 drop labelled polymer-
HRP.   
21. Spread with parafilm to ensure that the entire section is covered and incubate 
30 min room temperature.  
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22. Tap off the polymer solution onto paper towels prior to placing the slides in a 
staining dish filled with TBS. 
23. Incubate 5 minutes at room temperature. 
24. Decant TBS and refill. 
25. Incubate 5 minutes at room temperature. 
26. Prepare substrate/chromagen solution: 20%l/1ml substrate (require 50 %l per 
section). 
27. Tap off any remaining TBS, carefully wipe around the specimen and the back 
of the slides with a tissue to remove excess liquid. 
28. Return slides to the humidified chamber and apply 50 %l substrate/chromagen 
solution.   
29. Spread with parafilm to ensure that the entire section is covered and incubate 
10 min room temperature. 
30. Place slides in staining rack and immerse immediately in tap water to stop the 
reaction. 
31. Turn on fume hood in lab 4. 
32. Counterstain using filtered Gill 2 haematoxylin in lab 4.  Immerse for 1 min 
30s. 
33. Immerse in tap water and rinse until water is clear. 
34. Dip briefly in acid alcohol, and immediately back into tap water (5 min). 
35. Incubate 1 min in 70% ethanol.   
36. Blot off excess and incubate 1 min in 90% ethanol. 
37. Blot off excess and incubate 3 min in 100% ethanol. 
38. Repeat step 36. 
39. Blot off excess and incubate 5 min in xylene. 
40. Blot off excess and incubate 10 min in xylene. 
41. Remove a few slides at a time and apply sufficient DPX to cover the section. 
42. Choose an appropriately sized coverslip and apply to the slide. 
43. Remove air bubbles by using a cocktail stick or yellow pipette tip to gently 
press on the coverslip and “chase” bubbles to the edge. 
44. Leave to dry in fume hood. 
 
 
 
